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SUMMARY Polymyxins are well-established antibiotics that have recently regained
signiﬁcant interest as a consequence of the increasing incidence of infections due to
multidrug-resistant Gram-negative bacteria. Colistin and polymyxin B are being seri-
ously reconsidered as last-resort antibiotics in many areas where multidrug resis-
tance is observed in clinical medicine. In parallel, the heavy use of polymyxins in
veterinary medicine is currently being reconsidered due to increased reports of
polymyxin-resistant bacteria. Susceptibility testing is challenging with polymyxins,
and currently available techniques are presented here. Genotypic and phenotypic meth-
ods that provide relevant information for diagnostic laboratories are presented. This re-
view also presents recent works in relation to recently identiﬁed mechanisms of poly-
myxin resistance, including chromosomally encoded resistance traits as well as the
recently identiﬁed plasmid-encoded polymyxin resistance determinant MCR-1. Epidemio-
logical features summarizing the current knowledge in that ﬁeld are presented.
KEYWORDS Gram-negative bacteria, MCR-1, lipopolysaccharide, polymyxins, toxicity
INTRODUCTION
Colistin (also known as polymyxin E) is a polypeptide antibiotic that was originallyisolated in 1947 from the soil bacterium Paenibacillus polymyxa subsp. colistinus (1).
Colistin and polymyxin B belong to the class of polymyxins, which is one of the primary
classes of antibiotics with activity against most Gram-negative bacteria.
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Structure
The chemical structure of polymyxins is similar to that of cationic antimicrobial
peptides (CAMPs) (defensins and gramicidins), which represent the ﬁrst line of defense
against bacterial colonization in eukaryotic cells (2). Polymyxins are cationic polypep-
tides that consist of a cyclic heptapeptide possessing a tripeptide side chain acylated
at the N terminus by a fatty acid tail (3, 4) (Fig. 1). The inherent toxicity of colistin may
be explained by the hydrophobic properties of the N-terminal fatty acyl segment,
which also accounts signiﬁcantly for its antimicrobial activity, and also by positions 6
and 7, which are very important (5, 6).
Colistin and polymyxin B differ by only a single amino acid in the peptide ring, with
a phenylalanine in polymyxin B and a leucine in colistin (Fig. 1) (7). Polymyxin B is
administered directly as an active antibiotic, whereas colistin is administered as an
inactive prodrug, colistin methanesulfonate (also known as colistimethate [CMS]) (Fig.
1) (7).
The terms “colistin” and “colistimethate” are not interchangeable, since they corre-
spond to different forms of colistin available for clinical use (4). Indeed, colistimethate
sodium is a polyanionic inactive prodrug that is less toxic than colistin sulfate (Fig. 1)
(4, 8). Colistimethate is formed by the reaction of colistin with formaldehyde and
sodium bisulﬁte (9). This prodrug is transformed in aqueous media, and also in vivo in
biological ﬂuids, and is converted into colistin and several inactive methanesulfonated
compounds (10, 11).
Mechanism of Action
The target of polymyxins is the outer membrane of Gram-negative bacteria. Because
of an electrostatic interaction occurring between the ,-diaminobutyric acid (Dab)
residue of the positively charged polymyxin on one side and the phosphate groups of
the negatively charged lipid A membrane on the other side, divalent cations (Ca2 and
Mg2) are displaced from the negatively charged phosphate groups of membrane
lipids (12). The lipopolysaccharide (LPS) is therefore destabilized, consequently increas-
ing the permeability of the bacterial membrane, leading to leakage of the cytoplasmic
FIG 1 Structures of colistin A and B, colistimethate A and B, and polymyxin B1 and B2.
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content and ultimately causing cell death (4, 13). Note that even though the LPS is the
initial target, the exact mode of action of polymyxins still remains unclear.
Another antibacterial mechanism is the endotoxin effect. The endotoxin of Gram-
negative pathogens corresponds to the lipid A portion of the LPS; polymyxins have the
ability to bind to and neutralize this LPS molecule released during cell lysis (14).
Finally, another mode of action of the polymyxins is the inhibition of vital respiratory
enzymes (inhibition of type II NADH-quinone oxidoreductases [NDH-2]) in the bacterial
inner membrane (15).
Spectrum of Activity
Polymyxins have a narrow antibacterial spectrum, mainly against common Gram-
negative bacteria. They are active against most members of the Enterobacteriaceae
family, including Escherichia coli, Enterobacter spp., Klebsiella spp., Citrobacter spp.,
Salmonella spp., and Shigella spp. Polymyxins also have signiﬁcant activity against
common nonfermentative Gram-negative bacteria, including Acinetobacter baumannii,
Pseudomonas aeruginosa, and Stenotrophomonas maltophilia (13).
Conversely, some species are naturally resistant to polymyxins, including Proteus
spp., Morganella morganii, Providencia spp., Serratia marcescens, Pseudomonas mallei,
Burkholderia cepacia, Chromobacterium spp., Edwardsiella spp., Brucella, Legionella, Cam-
pylobacter, and Vibrio cholerae. Polymyxins are not active against Gram-negative cocci
(Neisseria spp.), Gram-positive bacteria, and anaerobic bacteria (13).
Pharmacodynamics
The antibacterial effect of colistin is concentration dependent (4, 16–18). The
pharmacokinetic-pharmacodynamic (PK-PD) index that best predicts the antibacterial
activity against A. baumannii and P. aeruginosa is the ratio of the area under the
concentration-time curve for free drug from 0 to 24 h to the MIC (fAUC0–24/MIC), with
this index being superior to the maximum concentration of drug in serum (Cmax)/MIC
relationship, suggesting that time-averaged exposure to colistin is more important than
the achievement of high peak concentrations (19–21). An average steady-state plasma
colistin concentration of 2 g/ml has been suggested as a reasonable target value for
isolates with MICs of 1 g/ml, maximizing the antimicrobial activity while minimizing
the risk of nephrotoxicity (22). An inadequate AUC/MIC ratio likely leads to treatment
failure. The colistin antibacterial effect is extremely rapid, occurring as early as 5 min
after exposure (17, 18, 23, 24).
A postantibiotic effect was observed against Klebsiella pneumoniae, P. aeruginosa,
and A. baumannii (25). However, it is important to highlight that polymyxins have
minimal postantibiotic effects at clinically relevant concentrations. Despite the major
initial killing rate observed against colistin-susceptible strains exposed to colistin alone,
regrowth has been reported for A. baumannii (17) and K. pneumoniae (18) in static
time-kill studies. Colistin heteroresistance, a phenomenon corresponding to the emer-
gence of a colistin-resistant subpopulation (that can grow in the presence of4 g/ml
of colistin) within a susceptible population (i.e., with a MIC of 2 g/ml), has been
observed for A. baumannii (26, 27), K. pneumoniae (18, 28), and P. aeruginosa (23).
USE OF COLISTIN IN HUMAN AND VETERINARY MEDICINE
Use in Human Medicine
After its discovery in 1947, colistin was used in Japan and Europe during the 1950s
(29). Then, after its approval by the U.S. FDA in 1959, colistimethate (CMS), the inactive
prodrug of colistin, replaced colistin for parenteral administration (29). Colistin and CMS
have been used widely for decades for treatment of infections caused by Gram-
negative bacteria. However, in the 1970s, because of their toxicity, especially nephro-
toxicity (30), their use was reconsidered. They were then replaced by novel, more active
and less toxic antibiotics, such as aminoglycosides, quinolones, and -lactams. For 20
years, the use of colistin was restricted to ophthalmic and topical uses. Systemic or
nebulized colistin was used only for cystic ﬁbrosis patients.
560
However, the increasing prevalence of multidrug-resistant (MDR) Gram-negative
bacteria (31), particularly K. pneumoniae, A. baumannii, and P. aeruginosa, has forced
physicians to reintroduce systemic polymyxin as a valuable therapeutic option (4,
13, 32).
Considering the paucity of novel antibiotics, colistin is currently often the only
effective antibiotic agent against MDR organisms, particularly carbapenemase-pro-
ducing bacteria.
Commercial formulations. There are more than 30 polymyxin molecules, among
which there are ﬁve main chemical compounds (polymyxins A to E), each containing
multiple components. Although colistin (polymyxin E) and polymyxin B are both used
in clinical practice (33), colistin is the most widely used polymyxin (23). The two most
common commercially available parenteral formulations of the colistin prodrug, CMS,
are Colomycin (Forest Laboratories UK Limited, Dartford, United Kingdom), primarily
employed in Europe, and Coly-Mycin M Parenteral (Monarch Pharmaceuticals, Inc.,
Bristol, TN), primilarily employed in the United States (34). Unfortunately, the vials of
both formulations contain different dry powder quantities, and the two products are
differently labeled, with Colomycin being labeled in international units (IU) of CMS and
Coly-Mycin M Parenteral being labeled in milligrams of CMS or colistin base activity
(CBA) (34). The conversion is as follows: 1 million units (MU) CMS  80 mg CMS  30
mg CBA (35). To add to the confusion, some other brands corresponding to generic
products are now available (36). The multiplicity of terms used to express contents of
vials and dose regimens unfortunately creates confusion and does not allow any
meaningful comparison of data collected from studies performed in different parts of
the world.
Routes of administration. Colistin sulfate can be administered orally as tablets and
syrup for selective digestive tract decontamination (no absorption) and topically for the
treatment of bacterial skin infections (13). CMS, the less toxic prodrug, has different
administration routes, i.e., parenteral (including intravenous) and intramuscular, but
intrathecal or intraventricular administration is also possible (13). The intramuscular
injection is rarely used in clinical practice because it may be very painful locally, and
also because its absorption is variable (33). Both colistin sulfate and CMS can be
delivered through inhalation by aerosol therapy, but there is a higher frequency of
bronchoconstriction with colistin sulfate (33). Delivery of CMS by inhalation and by the
intrathecal and intraventricular routes allows much higher concentrations in lung ﬂuid
and cerebrospinal ﬂuid, respectively, than those seen with systemic administration.
Moreover, those routes of administration lead to negligible plasma exposure and are
less toxic (in particularly less nephrotoxic) (22).
In aqueous solutions, colistimethate sodium is transformed into colistin; therefore, it
should be administered shortly after reconstitution to avoid the toxicity associated with
colistin (37).
Pharmacokinetics. Because of their discovery and their introduction into clinical use
more than 50 years ago, polymyxins were never subjected to the drug development
approval process currently required by international drug regulatory authorities. Con-
sequently, the PK and PD data on the rational use of polymyxins (maximizing antibac-
terial activity and minimizing toxicity and development of resistance) were not avail-
able until recently. The fact that, until recently, plasma concentrations of CMS and
formed colistin could not be differentiated because of a lack of suitable techniques was
another obstacle limiting progress in this area. The recent development of chromato-
graphic methods allowing quantitative assessment of each compound separately
signiﬁcantly contributed to the renewed interest in prescribing colistin and colistime-
thate (38, 39). It was clearly demonstrated that the observed antimicrobial activity
results from the action of colistin itself, which is generated in vivo when CMS is given.
For accurate PK information, a prerequisite is to quantify separately the inactive
prodrug (CMS) and the active entity (colistin) (34).
After its parenteral administration, a large proportion of CMS is eliminated mainly
through the kidneys by glomerular ﬁltration and tubular secretion (Fig. 2A) (11).
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Because in a healthy individual the clearance of CMS by the kidneys is much higher
than its conversion clearance to colistin, no more than 20 to 25% of a CMS dose is
hydrolyzed in vivo into an active colistin entity (7). Consequently, the colistin concen-
trations resulting from the original CMS administration are low. In contrast to CMS,
colistin is eliminated predominantly by a nonrenal way because of its extensive renal
tubular reabsorption (Fig. 2A) (11, 40). Although colistin is poorly excreted in urine, the
urinary concentration of colistin may be relatively high after administration of CMS due
to the conversion of CMS (highly excreted by the kidneys) into colistin within the
urinary tract (7).
In contrast to colistin, polymyxin B is administered directly in its active antibacterial
form. As for colistin formed from CMS, polymyxin B is subject to very extensive renal
tubular reabsorption and is thus eliminated mainly by a nonrenal clearance mecha-
nism(s) (Fig. 2B) (7).
Dosing regimen. Due to renewed interest in its use in the context of infections
caused by multidrug-resistant bacteria, and considering the increasing rates of resis-
tance to colistin currently observed, CMS has to be administered carefully. In particular,
the regimens allowing maximal antibacterial activity and minimal development of
resistance have to be deﬁned accurately, since the regimens need to minimize adverse
effects (23). A study analyzing product data characteristics of intravenous CMS revealed
a lack of uniformity between manufacturers, with quite broad variations in term of
indications, dose regimens (3 to 12 MU/day), and PK (36). Moreover, dosing regimens
given by manufacturers are often discordant with the dosing regimens recommended
by the recent literature (21, 34, 41).
(i) Patients with normal renal function. The currently used dosage regimens of CMS
generate suboptimal exposure to colistin in many critically ill patients, in particular in
renally competent patients. Two studies reported low plasma colistin Cmax values
FIG 2 Overview of the pharmacokinetic pathways for colistimethate (CMS) and colistin (A) and for
polymyxin B (B). The thicknesses of the arrows indicate the relative magnitudes of the respective
clearance pathways when kidney function is normal. CMS includes fully and all partially methanesulfon-
ated derivatives of colistin. After administration of CMS, extensive renal excretion of the prodrug occurs,
with some of the excreted CMS being converted to colistin within the urinary tract. (The ﬁgure is based
in part on data from reference 7.)
562
following administration of 174 mg to 250 mg (2 to 3 MU) of CMS every 8 or 12 h, with
steady-state levels of 1.15 to 5.14 g/ml or 0.68 to 4.65 g/ml, respectively (42).
Moreover, a signiﬁcant delay in obtaining steady-state plasma concentrations of
formed colistin was reported for CMS treatment started without administration of a
loading dose (43). In the latter study, concentrations of colistin in the plasma were
reported to be below the MIC breakpoint (2 g/ml), which is a main drawback
considering that a delayed initiation of appropriate antibiotic therapy has been shown
to be associated with increased mortality rates, in particular for critically ill patients (44).
In addition, low colistin concentrations may induce the ampliﬁcation of colistin-
resistant subpopulations (18, 45). Interestingly, on consideration of the current dose
range product recommendations for CMS, it was conﬁrmed that its administration at
the upper limit to patients with normal renal function resulted in low and potentially
suboptimal plasma colistin concentrations, especially when the MIC for the infecting
bacterial strain was in the upper range (2 g/ml) or if the infection was associated with
a high bacterial inoculum (21). That study also revealed that steady-state plasma
colistin concentrations are highly variable, with up to a 10-fold range achieved across
patients at a given creatinine clearance (21).
In contrast, there is a relatively low interpatient variability (3.3-fold) across a wide
range of creatinine clearance values following administration of polymyxin B (46).
Considering that polymyxin B is not given as a prodrug, it is easier to rapidly achieve
a desired plasma concentration of polymyxin B (46).
There is no consensus about dosing regimens, even though recently published
dosing suggestions seem to be widely accepted (19). Compared to those suggested by
the manufacturers, the regimens in recent studies support the administration of a
loading dose and of higher doses of CMS in order to achieve adequate colistin
concentrations leading to a better therapeutic effect (21, 41, 47). The dosing regimen
currently recommended by the recent literature (for patients with good renal function)
is a loading dose of 4.5 MU of CMS followed by maintenance doses of 4.5 MU twice
daily (48–50). A colistin-containing combination therapy has to be considered if the
infecting pathogen shows an MIC of colistin above 1 g/ml, if there is a high inoculum,
or in dealing with deep-seated infections (e.g., in lungs). One therefore has to consider
adding antibiotics to colistin regimens, especially for patients with relatively normal
renal function (21, 22).
Data about the pharmacokinetics, effectiveness, and safety of polymyxins were
recently reviewed by the European Medicines Agency (EMA). There have been recom-
mended changes in terms of product information in order to ensure the safer use of
polymyxins (51). According to the EMA, polymyxins should be reserved for the treat-
ment of serious infections due to aerobic Gram-negative pathogens with limited
treatment options (51). Also, they should be given with another suitable antibiotic
when possible. The recommended dose for CMS in adults is 9 MU daily in 2 or 3 divided
doses as a slow intravenous infusion. For dealing with critically ill patients, a loading
dose of 9 MU should be given. For patients with renal impairment, doses should
obviously be reduced, with consideration of the creatinine clearance.
Because the efﬁcacy and toxicity of colistin are dose dependent, it is crucial that
optimal dose regimens be used to maximize the antimicrobial activity and to minimize
adverse effects and the development of resistance. This is especially important for
critically ill patients, as they are most at risk for high morbidity and mortality (52).
(ii) Patients with renal insufﬁciency. A study showed that colistin levels were
elevated in patients with renal insufﬁciency, presumably due to decreased elimination
of the antibiotic generating a higher rate of conversion of CMS to colistin (43).
Development of nephrotoxicity is consequently higher in patients with renal insufﬁ-
ciency than in patients with normal renal function (53).
Dalﬁno et al. (54) suggested a new dose adjustment for high-dose colistin therapy
for patients with renal insufﬁciency. For patients with creatinine clearance of 20 to 50
ml/min, they recommend a loading dose of 9 MU and maintenance doses of 4.5 MU
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every 24 h. For patients with creatinine clearance of 20 ml/min, they recommend a
loading dose of 9 MU and maintenance doses of 4.5 MU every 48 h (21, 55).
Toxicity. Rates of toxicity following intravenous administration of CMS are consid-
ered lower today than those observed in previous studies, and it has to be mentioned
that the criteria for deﬁning toxicity have also been updated (56). The lower toxicity
may be related to the fact that there are fewer chemical impurities in CMS but also to
the fact that monitoring in intensive care units (ICUs) is better nowadays and the
coadministration of other nephrotoxic drugs is signiﬁcantly avoided (33).
Colistin has a narrow therapeutic window, and major adverse effects related to its
parenteral use are neurotoxicity and nephrotoxicity. Neurotoxicity is dose dependent
and reversible (55) and may cause peripheral and facial paresthesia, weakness, dizzi-
ness/vertigo, visual disturbances, confusion, ataxia, and neuromuscular blockade, even
leading to respiratory failure or apnea (56). The most common neurotoxicological effect
is paresthesia (occurring in 27% of patients), and there is no report of neuromuscular
blockade or apnea in the recent literature (56). Nephrotoxicity is the most common and
concerning adverse effect, especially with the newly recommended high-dose regimen.
Similarly to neurotoxicity, nephrotoxicity is dose dependent. The risk of colistin-
associated nephrotoxicity increases with plasma colistin concentrations above 2.5 to 3
g/ml, as revealed by recent PK-PD analyses (57). Other risk factors for nephrotoxicity
include coadministration of other drugs that are also nephrotoxic (anti-inﬂamatory
drugs, vancomycin, or aminoglycoside antibiotics) and patient-related factors (ad-
vanced age, male sex, hypoalbuminemia, hyperbilirubinemia, preexisting chronic kid-
ney disease, and severity of illness) (33, 56). Nephrotoxicity is reported to be a
rapid-onset effect, with most cases occurring within the ﬁrst week of treatment, and is
mostly reversible (33, 55). Rates of nephrotoxicity in recent studies ranged from 6% to
55% (33). The large range of nephrotoxicity rates may be explained partially by different
deﬁnitions of renal failure, the dosing regimens used, the concomitant administration
of nephrotoxic drugs, and the use of colistin monitoring to adapt dosing regimens. The
RIFLE (risk–injury–failure–loss–end-stage renal disease) classiﬁcation is used to deter-
mine colistin-associated nephrotoxicity (58).
Two recent comparative studies involving large numbers of patients showed that
the nephrotoxicity rates were lower for polymyxin B than for CMS/colistin (59, 60).
Use in Veterinary Medicine
As opposed to the case in human medicine, in veterinary medicine colistin has been
used extensively for decades for the treatment and prevention of infectious diseases. The
majority of polymyxin consumption corresponds to orally administered forms, with differ-
ent formulations (premix, powder, or oral solutions). The main usage is related to entero-
bacterial infections, and in particular to gastrointestinal infections caused by E. coli in
poultry and pigs within intensive husbandry systems (61). Apart from this common usage
for treating infections caused by Enterobacteriaceae, another usage corresponds to growth
promotion, which is a common practice worldwide. Furthermore, the fact that only a thin
line exists between oral metaphylactic therapy, preventive starter rations, and growth
promotion adds to the problem. In 2011, polymyxins were the ﬁfth most sold class of
antimicrobials (7%) for treating food-producing animals in Europe (61).
Despite this extensive use in veterinary medicine, the resistance rate to colistin in E.
coli strains recovered from healthy animals remains 1% in many European countries
(62). However, resistance to colistin has increasingly been reported (10%) among
porcine-pathogenic E. coli strains in Belgium (63), and the emergence of resistance has
been described for cattle (64). Moreover, some recent data revealed the possibility of
horizontal transmission from farm animals to humans in Asia (65). Given the increasing
need to retain the efﬁcacy of colistin to treat MDR infections in humans, the potential
for spreading colistin-resistant isolates from animals to humans, and the recent iden-
tiﬁcation of colistin-resistant Enterobacteriaceae organisms harboring a plasmid-borne
colistin resistance determinant in animals and food products (see below), the use of
colistin in veterinary medicine is being reevaluated. As a very recent example, the
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formal Ministry of Agriculture of China decided to ban colistin as a feed additive for
animals (66). Also, the European Medicines Agency provided a position paper in June
2016, in which updated advice on the use of colistin products in animals within the
European Union is provided (67).
METHODS FOR SUSCEPTIBILITY TESTING
Despite such a long term of clinical use (decades), the optimal method for polymyxin
susceptibility testing still remains undeﬁned. However, the recent emergence of MDR
Gram-negative bacteria and the subsequent increased use of colistin prompted the scien-
tiﬁc community to develop rapid and reliable methods to determine the susceptibility of
isolates to polymyxins, as this is now an urgent need in clinical laboratories. Polymyxin
susceptibility testing is now a major challenge, as human infections with colistin-resistant
Gram-negative bacteria are associated with higher patient mortality (68). The difﬁculties in
testing susceptibility to polymyxins are diverse, including poor diffusion of polymyxins into
agar, the inherent cationic properties of polymyxins, the occurrence of heteroresistance to
polymyxins in many species, and the lack of a reliable reference method that may allow
reliable comparisons of commercial tests (69, 70).
Dilution Methods
The aim of dilution methods is to determine the MIC, corresponding to the lowest
concentration of polymyxin that inhibits visible bacterial growth after an incubation of
16 to 24 h at 35  2°C.
Broth dilution methods. Broth dilution is a technique in which a bacterial suspen-
sion at a predetermined concentration is tested against various concentrations of
antimicrobial agent in a liquid medium with a predetermined formulation. Two types
of broth dilution methods are available: (i) the broth macrodilution method, performed
with a minimum volume of 2 ml in standard test tubes; and (ii) the broth microdilution
(BMD) method, performed with a volume of 0.05 to 0.1 ml in microtitration trays.
(i) Broth microdilution method. BMD is the reference susceptibility test method. It
is currently the only method recommended by the Clinical and Laboratory Standards
Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) (71, 72) for polymyxin antimicrobial susceptibility testing.
According to CLSI recommendations, BMD is performed with cation-adjusted
Mueller-Hinton broth (CA-MHB), a range of 2-fold dilutions of polymyxins (ranging from
0.12 to 512 g/ml), and a ﬁnal bacterial inoculum of 5  105 CFU/ml in each well (73).
BMD is considered to be the optimal method and is currently recommended for
susceptibility testing in the recent document proposed by the joint CLSI-EUCAST
Polymyxin Breakpoints Working Group (http://www.eucast.org/ﬁleadmin/src/media
/PDFs/EUCAST_ﬁles/General_documents/Recommendations_for_MIC_determination
_of_colistin_March_2016.pdf).
However, BMD is quite laborious, and manual preparation (if the technique used is
not an automated one) of antibiotic solutions may lead to signiﬁcant errors. It is
therefore not adaptable for most clinical microbiology laboratories. Furthermore, non-
reproducible and noninterpretable MIC results have been reported due to the presence
of skip wells (i.e., wells that exhibit no growth, whereas growth is observed in wells with
higher antibiotic concentrations) for Enterobacter species (69), P. aeruginosa (72), and A.
baumannii (73). This phenomenon might be caused by heteroresistant subpopulations
for Enterobacter spp. (69). In parallel, “skip well” isolates of P. aeruginosa have been
found to have increased expression of the pmrAB, phoQ, and arn genes related to
changes in the LPS structure, reducing the potential binding sites of polymyxins (74).
Nevertheless, BMD currently remains the reference method for determination of
MICs because of its reproducibility, reliability, and possibility of automation.
(ii) Broth macrodilution method (or tube dilution method). The growth medium
(CA-MHB), the inoculum bacterial suspension, the preparation of 2-fold dilutions of
polymyxins, the incubation conditions, and the reading of the plate are identical to
those for the broth microdilution method. The only difference is the volume of growth
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medium and the use of test tubes instead of trays. When evaluated against BMD results,
the results of the broth macrodilution method showed the highest agreement (83%)
compared to other available methods, and no false susceptibility was observed (70).
Agar dilution method. Agar dilution is another reference method that relies on
various concentrations of polymyxin molecules in Mueller-Hinton agar (usually 2-fold
serial dilutions), followed by the seeding of a deﬁned bacterial inoculum onto the agar
plate. In accordance with the CLSI recommendations, the polymyxin powder is dis-
solved in sterile water and added to molten MH agar to provide 2-fold dilutions (usually
ranging from 0.12 g/ml to 512 g/ml) (70, 71). A bacterial inoculum corresponding to
a 0.5 McFarland standard (approximately 108 CFU/ml) is prepared, and then 10-fold
dilutions are performed. One microliter of this dilution is spotted manually or with an
automated system, and each spot consequently inoculates 104 CFU of bacteria.
Agar dilution may theoretically avoid the adsorption of colistin to the plates, but no
study has measured the colistin concentration in agar dilution plates to conﬁrm this
hypothesis. Numerous studies have demonstrated a strong correlation between agar
dilution and BMD (70, 75, 76), with the exception of results obtained with P. aeruginosa
and S. maltophilia isolates from cystic ﬁbrosis patients (77, 78). One advantage of the
agar dilution method is the ability to test multiple strains on the same plate and the
possibility to semiautomate the method. However, the agar dilution method also
presents some disadvantages, as it is very laborious if not automated and the plates
(not available from commercial sources) must be used within a week of preparation.
Many studies have employed the agar dilution method as a standard; however, BMD
remains the primary reference method for polymyxin MIC testing. In a recent document
proposed by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group, it is stated
that agar dilution is not recommended for susceptibility testing (http://www.eucast
.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/General_documents/Recommendations
_for_MIC_determination_of_colistin_March_2016.pdf).
Routine Susceptibility Testing Methods
Nonautomatic systems. (i) DD test (Kirby-Bauer procedure). The disk diffusion (DD)
test refers to the diffusion of a given concentration of polymyxin from disks into MH
agar that has been seeded with a deﬁned bacterial inoculum. According to the CLSI and
EUCAST guidelines, the disk diffusion test is performed by applying a bacterial inocu-
lum corresponding to a 0.5 McFarland standard (approximately 108 CFU/ml) suspended
in 0.85% NaCl onto the entire surface of an MH agar plate by use of a sterile cotton
swab. Paper disks impregnated with polymyxin are placed on the inoculated agar
surface. Following the CLSI guidelines, the contents of colistin and polymyxin B on the
paper disks are 10 g and 300 U, respectively (72), while following the EUCAST
recommendations, the colistin content is 50 g (71). The growth inhibition zone
diameter around the disk is measured after incubation for 16 to 24 h at 35  2°C. The
diameter of the inhibition zone is proportional to the bacterial susceptibility to poly-
myxins and inversely correlates with the MIC of the bacterial strain.
The DD test is easy and cheap and does not require speciﬁc equipment. These
advantages explain why this method is commonly used as a primary test method to
screen large numbers of isolates. However, the poor and slow diffusion of polymyxins
through agar gives small zones of inhibition and limits the predictive accuracy of the
DD test. In fact, many studies showed that the DD test is a nonreliable method for
measuring susceptibility to colistin for Gram-negative rods, giving an unacceptable and
very high rate of false susceptibility (up to 35%) compared to that with dilution
methods (76, 78–80). A higher concentration of colistin in the disk (50 g as recom-
mended by EUCAST versus 10 g as recommended by CLSI) does not improve the
reliability of the test (80). Susceptible results should therefore be conﬁrmed by dilution
tests. On the other hand, no false resistance results are found with this method (80).
This method is not reliable and should be abandoned. For human medicine, EUCAST
recommends that precise MIC determination be mandatory before clinical use and no
longer provides disk breakpoints (71). For veterinary medicine, EUCAST recommends
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precise determination of the MIC each time that the diameter of the inhibition zone is
between 15 and 18 mm for a given strain.
(ii) Etest strips. Etests are thin plastic test strips impregnated with increasing
antibiotic concentrations. MICs are read with the concentration scale marked on the
upper surface. According to the manufacturer’s recommendations, this method is
performed by applying a bacterial inoculum of approximately 108 CFU/ml (turbidimetry
of a 0.5 McFarland standard) suspended in 0.85% NaCl onto the entire surface of an MH
agar plate by use of a sterile cotton swab. Etest strips containing a colistin concentra-
tion gradient (ranging from 0.016 to 256 g/ml) are placed on the inoculated agar
surface, and the MIC is determined after incubation for 16 to 24 h at 35  2°C. The MIC
value is deﬁned by the intersection of the lower part of the ellipse-shaped growth
inhibition area with the test strip. When the intersection occurs around the MIC
endpoint, the highest MIC intersection is recorded (75). When small colonies grow
within the zone of inhibition, the strain must be considered heteroresistant to colistin,
and the highest MIC intersection is recorded (75, 81).
Several studies, notably including few resistant isolates, found an excellent correla-
tion between the Etest and reference techniques (75, 76, 80, 82). However, studies
including larger numbers of resistant isolates reported high rates of false susceptibility
(up to 32%) for Gram-negative rods compared to those with dilution methods (69, 70,
78, 83). The Etest method may fail to detect resistance to colistin even when isolates
exhibit high MICs by dilution methods (70, 83). In addition, there are discrepancies
between MICs measured by Etest and MICs measured by dilution methods (70, 82). It
has been reported that the Etest strip method underestimates the level of resistance of
polymyxin-resistant strains (MIC  4 g/ml) and overestimates the MIC values for
susceptible strains (MIC  4 g/ml) (70).
This method is easy to perform but is relatively expensive and does not reliably
detect colistin-resistant isolates. As for the disk diffusion test, susceptibility results
obtained by Etest require a 24-h delay.
(iii) UMIC system. The UMIC system (Biocentric) consists of broth microdilution
unitary panels in which the wells contain prediluted lyophilized colistin at concentra-
tions ranging from 0.06 to 64 g/ml. The inoculation is performed manually, and the
required incubation time ranges from 18 to 24 h. The performance of this system has
not yet been evaluated.
Automatic systems. Use of instruments may allow susceptibility testing to be
performed in a shorter period than that required for manual methods, as the sensitive
optical detection systems of current instruments measure subtle changes in bacterial
growth. To date, four automated instruments capable of measuring susceptibility to
polymyxins are available. Two of them generate overall rapid (4 to 16 h) susceptibility
test results (Vitek 2 and Phoenix), while the others (MicroScan and Sensititre) are
overnight systems. These systems are associated with computer software to interpret
susceptibility results.
(i) Vitek 2 system. The Vitek 2 system (bioMérieux) uses plastic reagent cards that
contain microliter quantities of antibiotics and test media in wells (84). It tests colistin
concentrations ranging from 0.5 to 16 g/ml and monitors turbidimetry to determine
bacterial growth during a period of 4 to 10 h. Compared to dilution methods, the Vitek
2 system displays a low sensitivity for detecting colistin-resistant Gram-negative isolates
(83) and is not reliable for detecting heteroresistant subpopulations (76).
(ii) Phoenix automated microbiology system. The BD Phoenix automated micro-
biology system (BD Diagnostics) has a large incubator reader. Panels test colistin
concentrations ranging from 0.5 to 4 g/ml, and the inoculation is manual or automatic
(84). MIC results are generated in 6 to 16 h. No study has evaluated the performance
of Phoenix for detection of colistin resistance among Gram-negative bacteria. The only
published study evaluating polymyxin susceptibility by using the Phoenix system
unfortunately did not include colistin-resistant strains (85). Nevertheless, we recently
evaluated the accuracy of this system by testing 100 enterobacterial isolates (60
colistin-resistant and 40 colistin-susceptible isolates) and found a high rate (15%) of
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false-susceptible results. We observed a low sensitivity for detecting colistin heterore-
sistance in K. pneumoniae and Enterobacter cloacae isolates (our unpublished data) but
a good sensitivity for detecting plasmid-mediated colistin resistance.
(iii) MicroScan system. The MicroScan system (Beckman Coulter Diagnostics) uses
microdilution trays with colistin concentrations of 2 and 4 g/ml. The trays are
inoculated manually and incubated in the instrument for 16 to 20 h (84). Compared to
dilution methods, the categorical agreement of the MicroScan system is 87% for
Acinetobacter isolates (86), and the sensitivity is 88% for detection of polymyxin B
resistance in K. pneumoniae isolates (87).
(iv) Sensititre system. The Sensititre system (Thermo Fisher Scientiﬁc) is an auto-
mated incubation and reading system (84). The tests are standard broth microdilution
panels containing prediluted ranges of lyophilized colistin within the wells (0.12 to 128
g/ml). Inoculation may be performed by using a Sensititre autoinoculator. Growth is
measured after an incubation of 18 to 24 h. A single study has evaluated the Sensititre
method, and a 96% categorical agreement with BMD was found, with no false suscep-
tibility results reported (70).
Impact of Materials on MIC Determination
Impact of medium. Polymyxin resistance is regulated by the two-component
systems PhoP/PhoQ and PmrA/PmrB (88), which respond to cation (calcium, iron, and
magnesium) concentrations and pH variations. These systems are involved in the LPS
modiﬁcations leading to polymyxin resistance.
There is a high variability of cation concentrations in MH medium depending on the
commercial brand, and calcium and magnesium concentrations measured for each
brand tested are far below the recommendations of the CLSI (89). This is why the CLSI
recommends cation-adjusted MH or supplementation of the culture medium with
cations (72, 73).
Iso-Sensitest agar is a well-deﬁned medium with stabilized mineral content that was
developed to overcome problems associated with traditional media used for antimi-
crobial susceptibility tests. Comparison of the agar dilution and Etest methods on MH
and Iso-Sentitest agar (76) revealed a lack of detection of the resistant subpopulation
of heteroresistant E. cloacae isolates for the Etest performed on MH agar, while
Iso-Sensitest agar was more sensitive for detecting the resistant subpopulation with
both methods (76).
However, a cation-dependent inhibition of antimicrobial activity has been reported
for polymyxin antibiotics (90, 91). In fact, it is suspected that the colistin antimicrobial
activity might be overestimated if tested using conventional cation-adjusted MH as
recommended by the CLSI. Note that the calcium concentration recommended by the
CLSI for determining colistin susceptibility in vitro is 2-fold higher than the concentra-
tion found in human interstitial space ﬂuid in vivo (92). A recent study revealed that the
MIC of colistin might be misestimated if tested with conventional cation-adjusted
growth media (overestimation for P. aeruginosa and A. baumannii and underestimation
for E. coli) (92). The use of cation-adjusted or non-cation-adjusted medium therefore
remains questionable, and a consensus is still needed.
Impact of powder composition. MIC testing is performed using commercially
available polymyxin B and colistin sulfate powders. The variability in the relative
proportions of the mixture components between powder batches and manufacturers
is a potential source of variability of the results (93, 94). In parallel, MICs obtained using
BMD with puriﬁed forms of the major compounds of polymyxin B were within a log2
dilution of the MICs obtained using the U.S. Pharmacopoeia polymyxin B sulfate
powder mixture (95). These data suggest that the powder composition may not have
an impact on polymyxin susceptibility testing. Note that CMS, as a prodrug, cannot be
used for susceptibility testing, as it yields erroneously high MIC values (96).
Impact of the composition and treatment of plates. Due to their cationic proper-
ties, polymyxins adhere to the negative charges of the microtiter trays commonly used
for BMD. Karvanen et al. (97) measured the colistin concentrations following incubation
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in polypropylene, polystyrene, and glass tubes. The adsorption was proportionally
higher at lower concentrations of the drug. Consequently, the results of colistin BMD
measurements signiﬁcantly differ if tests are conducted in microtiter plates with
different coated wells (98). The amount of colistin adsorbed to the plate surface
therefore depends on various factors, such as the coating applied to the plate, and is
not consistent from well to well (K. Sei, presented at the January 2012 Meeting of the
CLSI Subcommittee on Antimicrobial Susceptibility Testing, Tempe, AZ, 22 to 24
January 2012). Since the nature and treatment of plastics are not addressed in the CLSI
recommendations, signiﬁcant variability is observed between laboratories performing
the reference BMD method.
Presence or absence of P-80. Polysorbate 80 (P-80 or Tween 80) is a surfactant used
for the preparation of BMD panels used for susceptibility testing (99). This surfactant
has been recommended by the CLSI to prevent or at least mitigate binding of
lipoglycopeptides to plastics (72, 73). The presence of 0.002% P-80 mitigates colistin
adsorption to polystyrene microplates (Sei, presented at the January 2012 Meeting of
the CLSI Subcommittee on Antimicrobial Susceptibility Testing). When P-80 is added
to a ﬁnal concentration of 0.002% in the well, the polymyxin MICs are 4- to 8-fold
lower than those obtained without P-80 among isolates with low MICs by BMD
testing (70, 99).
It is noteworthy that the effect of P-80 on bacterial viability has not been well
evaluated. Also, another concern is that P-80 may act synergistically with polymyxins,
consequently giving artiﬁcially lower MICs (100). Also, in P. aeruginosa, P-80 increases
cell permeability and lyses spheroblasts (101). On the other hand, polymyxins desta-
bilize the outer membrane, allowing P-80 to access the inner membrane and induce cell
lysis. Therefore, isolates resistant to polymyxins would not be affected signiﬁcantly by
P-80. Therefore, only isolates with polymyxin MICs of 1 g/ml might be affected (94).
In January 2014, the CLSI subcommittee decided to pursue a recommendation of
polymyxin BMD testing without P-80. However, if a susceptibility breakpoint of 1
g/ml is chosen, the ability to detect susceptible isolates without using P-80 may be
compromised (94). Since the use of P-80 is still questionable, a solution might be to
determine MICs in glass plates, as colistin ﬁxation on glass is less extensive (94).
However, glass plates are fragile and expensive.
Impacts of Subcultures and Storage on MICs
Impact of subcultures. A study by Li et al. (26) revealed a loss of colistin resistance
when resistant isolates were subcultured without selective pressure. For instance, about
98% of a colistin-resistant A. baumannii population lost the resistance phenotype after
a single passage in a colistin-free medium.
Impact of storage. A loss of colistin resistance was also observed after 6 to 8 months
of storage at 70°C (70). Among 25 isolates that initially tested resistant by a dilution
method, ﬁve (20%) tested susceptible by the same method after freezing. The avail-
ability of easy, rapid, and inexpensive techniques allowing screening of colistin resis-
tance on fresh cultures in routine laboratories is consequently a real clinical need.
Interpretive Criteria
There is a lack of consensus between the two organizations setting up breakpoints
for polymyxins, namely, the CLSI in the United States (72) and EUCAST in Europe (71).
The zone diameter and MIC interpretive criteria given by those two organizations for
colistin and polymyxin B are shown in Table 1. However, recent data related to PK
suggest that the current breakpoints might be too high (21).
Quality Controls
Quality control organisms are required during susceptibility testing in order to
ensure accuracy and standardization of the procedures. Quality control can be assessed
using the E. coli ATCC 25922 (NCTC 12241; CIP 76.24) and P. aeruginosa ATCC 27853
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(NCTC 12903; CIP 76110) reference strains. The disk diffusion and MIC quality control
ranges for these strains determined by the CLSI are shown in Table 2 (72).
Correlation between MICs of Colistin and Polymyxin B
Despite the high similarity of the molecular structures of colistin and polymyxin B,
a recent study including 15,377 Gram-negative bacteria revealed differences between
the MICs of colistin and polymyxin B (102). MIC values determined by the Sensititre
system were 2-fold higher for polymyxin B than for colistin for 55% and 53% of
Klebsiella species isolates (n  4,177) and E. coli isolates (n  6,311), respectively.
However, a categorical agreement of 99% was obtained for enterobacterial strains
when breakpoints of2/4 for both colistin and polymyxin B were applied. That study
showed a high level of agreement between MICs of colistin and polymyxin B for P.
aeruginosa and Acinetobacter spp.
Qualitative Detection Techniques
Rapid detection of heterogeneous populations among colistin-resistant Gram-
negative bacteria by use of capillary electrophoresis. Sautrey et al. (103) proposed a
capillary electrophoresis method for rapid detection of heterogeneous populations of
colistin-resistant strains. However, further development is required for such applica-
tions to be used in clinical laboratories on a daily basis.
Rapid detection of colistin-resistant A. baumannii isolates by use of the Micromax
assay. The Micromax assay is based on the detection of released nucleotides, indicating
cell wall damage, in the presence of colistin (104). After incubation with 0.5 g/ml of
colistin, strains are considered resistant to colistin if 11% of bacteria present cell wall
damage. Bacteria are incubated for 90 min in Mueller-Hinton broth to achieve expo-
nential growth and then incubated for 60 min with colistin at concentrations of 0 and
0.5 g/ml, respectively. Bacteria embedded in agarose are incubated with a lysis
solution removing only weakened cell walls. The released fragmented DNA may be
stained with the ﬂuorochrome SYBR gold (Molecular Probes, Eugene, OR) and visualized
by ﬂuorescence microscopy (45 min to 60 min of technical processing and scoring
under the microscope). This method is faster than the routine automatic microdilution
TABLE 1 Colistin and polymyxin B breakpoints according to CLSI and EUCAST in 2014
Criteria and
bacterial group
Colistin
Disk
content
(g)
Zone diam interpretative
criteria (mm)a
MIC interpretative criteria
(g/ml)a
Sensitive (S) Resistant (R) S Intermediate (I) R
CLSI criteria
Enterobacteriaceae — — — — —
Acinetobacter spp. — — 2 — 4
Pseudomonas spp. 10 11 10 2 4 8
EUCAST criteria
Enterobacteriaceae 50 18b,c 15b,c 2 — 2
Acinetobacter spp. —c —c 2 — 2
Pseudomonas spp. —c —c 4 — 4
a—, not determined or absent.
bZone diameter interpretative criteria for Enterobacteriaceae given by EUCAST are only for veterinary medicine; M
from 15 to 18 mm.
cNo zone diameter interpretative criteria for human medicine; the MIC must be determined before use.
TABLE 2 Zone diameter and MIC quality control ranges for polymyxins according to CLSI
guidelines
Strain
Zone diam (mm) range MIC (g/ml) range
Colistin Polymyxin B Colistin Polymyxin B
E. coli ATCC 25922 11–17 13–19 0.25–2 0.25–2
P. aeruginosa ATCC 27853 11–17 14–18 0.5–4 0.5–2
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procedure (3 h 30 min versus 6 to 8 h) and is accurate for detecting colistin resistance
in A. baumannii (100% sensitivity and 96% speciﬁcity). Another advantage is that it can
be automated. However, the manual task and the cost of the materials (ﬂuorochrome
and epiﬂuorescence microscope) are disadvantages for its routine use.
Rapid detection of colistin-resistant Enterobacteriaceae isolates by use of the
Rapid Polymyxin NP test. We developed the Rapid Polymyxin NP test, which is based
on the detection of bacterial growth in the presence of a deﬁned polymyxin concen-
tration (105). Detection is based on detection of glucose metabolism upon bacterial
growth. Glucose metabolism induces the formation of acid, leading to a color change
of the red phenol used as a pH indicator. The test is performed with a ﬁnal concen-
tration of bacteria of ca. 108 CFU/ml in each well (or tube), and the ﬁnal concentration
of polymyxin is 3.75 g/ml. Visual inspection of the tray is made after 10 min and then
every hour for 2 h. The test is considered positive (indicating polymyxin resistance) if
the isolate grows in the presence of colistin (color change from orange to yellow), while
it is considered negative (indicating polymyxin susceptibility) if the isolate does not
grow in the presence of polymyxin (no color change). This test is rapid (less than 2 h)
and easy to perform.
By testing a total of 200 enterobacterial isolates exhibiting either resistance (intrinsic
or acquired, or various) or susceptibility to polymyxins, the speciﬁcity and sensitivity of
this test were evaluated at 99.3% and 95.4%, respectively, compared to BMD as the
reference method (105). Note that the Rapid Polymyxin NP test identiﬁed the isolates
exhibiting a heteroresistance phenotype as well as those producing the plasmid-
mediated MCR-1 determinant (see below).
For the Rapid Polymyxin NP test, the adequate culture media for culturing the
bacteria prior to the test were Mueller-Hinton agar, Luria-Bertani agar, Columbia agar
plus 5% sheep blood, chocolate agar, UriSelect 4 agar, and eosin methylene blue agar.
The Rapid Polymyxin NP test may also detect colistin-resistant Enterobacteriaceae
directly from blood cultures (106). Results are obtained within 4 h.
Selective medium. So far, no selective medium allowing screening for any type of
polymyxin-resistant Gram-negative isolates (with intrinsic, chromosomally encoded, or
plasmid-mediated polymyxin resistance) has been available. Neither commercial nor
in-house screening culture media had been designed that might permit screening of
patients possibly colonized by polymyxin-resistant isolates. Therefore, we developed
SuperPolymyxin, a selective culture medium for detection of any type of polymyxin-
resistant Gram-negative organism (107). The SuperPolymyxin medium prevents swarm-
ing of Proteus spp. (intrinsically resistant to polymyxins) and also the growth of
Gram-positive bacteria and fungi, by addition of daptomycin and amphotericin B,
respectively. Its base corresponds to the eosin methylene blue medium (Levine’s
medium) (108) selective for Gram-negative bacteria, which differentiates lactose fer-
menters (black colonies) from nonfermenters (colorless or light lavender colonies). In
addition, differentiation of lactose fermenters is also possible to some extent. The
SuperPolymyxin medium contains a colistin concentration (3.5 g/ml) that allows clear
categorization between polymyxin-resistant and -susceptible isolates. The sensitivity
and speciﬁcity of this medium have been found to be 100% (107).
Genotypic Methods
Although the mechanisms underlying resistance to polymyxins have not all been
elucidated, acquisition of colistin resistance in Gram-negative bacteria has been attrib-
uted to lipopolysaccharide (LPS) modiﬁcations via diverse routes, including (i) the
addition of cationic groups to the LPS reducing the overall negative charge of the LPS
and consequently preventing the ﬁxation of polymyxins; (ii) loss of the LPS and,
consequently, loss of the polymyxin target; (iii) the overproduction of capsule polysac-
charide (CPS) hiding polymyxin binding sites; and (iv) the release of CPS trapping
polymyxins. Speciﬁc modiﬁcations of outer membrane porins and overexpression of
efﬂux pump systems have also been described (88).
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Several molecular mechanisms have been associated with colistin resistance in
Gram-negative bacteria, such as alterations in the PmrA/PmrB, PhoP/PhoQ, ParR/ParS,
ColR/ColS, and CprR/CprS two-component systems and alterations in the mgrB gene,
which encodes a negative regulator of PhoPQ. Mutations leading to the addition of
cationic groups on lipid A result in a less anionic lipid A and, consequently, to less
ﬁxation of polymyxins (88).
Similarly, alterations in the lpxA, lpxC, and lpxD genes of A. baumannii result in
inactivation of lipid A biosynthesis, leading to a complete loss of LPS and, consequently,
to a loss of the polymyxin target (109).
The mechanisms of polymyxin resistance can be identiﬁed by sequencing those
speciﬁc genes. However, molecular techniques cannot be envisioned in the near future
considering that (i) many chromosomally encoded mechanisms of resistance remain to
be identiﬁed, (ii) it is difﬁcult to extrapolate whether some substitutions identiﬁed in
proteins known to be involved in LPS biosynthesis lead to resistance, and (iii) the levels
of expression of the corresponding genes may vary and consequently inﬂuence the
level of resistance to polymyxins.
There is an exception that corresponds to the recent identiﬁcation of the plasmid-
borne mcr-1/mcr-2 genes, whose products confer resistance to polymyxins (see below).
According to the current knowledge on the topic, identiﬁcation of these genes may be
considered a signature of resistance or reduced susceptibility to polymyxins. This is why
identifying the gene makes sense in this case, since qualitative genetic results may be
translated directly into a nonsusceptibility phenotype. Screening of both mcr-1 and
mcr-2 can be performed by using a standard PCR protocol using the primers
MCR-1/2-Fw (5=-TAT CGC TAT GTG CTA AAG CC-3=) and MCR-1/2-Rv (5=-TCT TGG TAT
TTG GCG GTA TC-3=), giving rise to a 715-bp amplicon. Also, a SYBR green-based
real-time PCR assay that provides a simple, speciﬁc, sensitive, and rapid molecular
tool for detection of mcr-1-positive isolates was recently published (110). That
technique was validated on human and animal isolates and may be applied to
extensive surveillance studies.
Porin mutations and overexpression of efﬂux pump systems may also be involved in
colistin resistance (88), and it is very likely that phenotypic resistance to polymyxins in
clinical isolates often results from combined resistance mechanisms (e.g., defects in outer
membrane proteins combined with structural modiﬁcation of the LPS). Phenotypic meth-
ods, such as the Rapid Polymyxin NP test, are consequently very relevant for determining
the subsequent therapeutic decision, since they actually concretely determine the suscep-
tibility or lack thereof of isolates, in contrast to genotypic methods, which detect only
potential resistance and require sequencing of multiple genes.
RESISTANCE MECHANISMS IN ENTEROBACTERIACEAE
Intrinsic Resistance Mechanisms in Proteus mirabilis and Serratia marcescens
In P. mirabilis and S. marcescens, naturally occurring resistance to polymyxins is
linked to the constitutive expression of the arnBCADTEF operon and/or the eptB gene,
causing addition of phosphoethanolamine (pEtN) and/or 4-amino-4-deoxy-L-arabinose
(L-Ara4N) cationic groups to the LPS. This modiﬁcation increases the charge of the LPS,
which is the initial target of the polymyxins, and therefore decreases polymyxin
binding, giving rise to intrinsic resistance of these species (111–113).
Mechanisms Responsible for Acquired Resistance in Enterobacteriaceae
Acquired resistance to polymyxins has been identiﬁed in several genera of the
Enterobacteriaceae, such as Klebsiella, Escherichia, Enterobacter, and Salmonella. Colistin
resistance mechanisms remain unknown for some bacterial species, but several
molecular mechanisms have been identiﬁed. The most common is modiﬁcation of
the LPS via cationic substitution, similar to that observed in bacteria with intrinsic
resistance to polymyxins. A single transferable mechanism of resistance has been
identiﬁed so far (see below), with most of the resistance mechanisms being
encoded chromosomally.
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Similar to what is observed in strains that are naturally resistant to colistin, addition
of cationic groups (L-Ara4N and pEtN) to the LPS is responsible for acquisition of colistin
resistance in Enterobacteriaceae. A large panel of genes and operons are involved in
qualitative modiﬁcation of the LPS (Fig. 3), including genes and operons coding for
enzymes that are directly involved in LPS modiﬁcations (genes responsible for synthesis
of cationic groups and/or their addition to the LPS), i.e., the pmrC gene, the pmrE gene,
and the pmrHFIJKLM operon; regulatory genes, such as those encoding proteins
involved in the PmrAB and PhoPQ two-component systems; and the regulators of these
two-component systems, i.e., the mgrB gene, which negatively regulates the PhoPQ
system, and the newly described crrAB two-component regulatory system, which
regulates the PmrAB system.
Genes encoding LPS-modifying enzymes. (i) The pmrC gene. The pmrCAB operon
codes for three proteins, namely, the phosphoethanolamine (pEtN) phosphotransferase
PmrC, the response regulator PmrA (also called BasR), and the sensor kinase protein
PmrB (also called BasS) (114). The phosphoethanolamine phosphotransferase PmrC
adds a pEtN group to the LPS (Fig. 3) (114).
(ii) The pmrHFIJKLM operon and the pmrE gene. The pmrHFIJKLM operon (also
called the arnBCADTEF or pbgPE operon) codes for a total of seven proteins (115). The
pmrE gene and the pmrHFIJKLM operon are responsible for the synthesis of the
L-aminoarabinose group (L-Ara4N) and its ﬁxation to lipid A (Fig. 3) (115).
(iii) The pmrA and pmrB genes, which encode the PmrAB two-component system.
Environmental stimuli, such as macrophage phagosomes, ferric (Fe3) iron, aluminum
(Al3), and low pH (e.g., pH 5.5), mediate activation of PmrB through its periplasmic
domain (114). The PmrAB and PhoPQ two-component systems are normally activated
when bacteria are phagocytized into macrophages, allowing bacterial survival (114).
PmrB is a protein with tyrosine kinase activity that activates PmrA by phosphoryla-
tion. PmrA in turn activates the transcription of the pmrCAB operon, the pmrHFIJKLM
operon, and the pmrE gene involved in LPS modiﬁcation (pEtN and L-Ara4N addition)
(Fig. 3) (114).
Speciﬁc mutations within the pmrA and pmrB genes have been described as being
responsible for acquired colistin resistance in K. pneumoniae (105, 116–120), Enterobac-
FIG 3 Regulation pathways of LPS modiﬁcations in Klebsiella pneumoniae.
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ter aerogenes (121), and Salmonella enterica (122, 123) (Table 3). These mutations are
responsible for constitutive activation of the PmrAB two-component system, leading to
upregulation of the pmrCAB operon, the pmrHFIJKLM operon, and the pmrE gene, and
thus to the synthesis of pEtN and L-Ara4N and their transfer to lipid A (Fig. 3).
Some polymorphism in the pmrAB genes of colistin-resistant E. coli has been
reported (124, 125), but the involvement of these mutations in the colistin resistance
phenotype has not formally been demonstrated, since no complementation or site-
directed mutagenesis has been performed.
(iv) The phoP and phoQ genes, which encode the PhoPQ two-component system.
The phoPQ operon codes for two proteins, namely, the regulator protein PhoP and the
sensor protein kinase PhoQ. Environmental stimuli, such as macrophage phagosomes,
low magnesium (Mg2), and low pH (e.g., pH 5.5), mediate activation of PhoQ through
its periplasmic domain (114). The PhoPQ two-component system allows the expression
of genes that code for magnesium transport, enzymes that modify the LPS to allow
resistance to cationic antimicrobial peptides, and enzymes that decrease the cell stress
caused by acidic pH or some virulence factors (126, 127). The PhoPQ two-component
system therefore allows bacterial survival under conditions of low magnesium or acidic
pH or in the presence of cationic antimicrobial peptides.
PhoQ is a protein with tyrosine kinase activity that activates PhoP by phosphoryla-
tion. PhoP in turn activates the transcription of the pmrHFIJKLM operon, involved in the
addition of L-Ara4N to the LPS (Fig. 3) (126, 127). PhoP can also activate the PmrA
protein, either directly or indirectly via the PmrD connector protein, causing the
addition of pEtN to the LPS.
Several mutations in the phoP and phoQ genes are responsible for acquired resis-
tance to polymyxins in K. pneumoniae (81, 105, 117, 118, 120, 128) (Table 3). One
mutation potentially involved in colistin resistance in E. coli has also been described
(65). These mutations are responsible for constitutive activation of the PhoPQ two-
component system, leading to upregulation of the pmrHFIJKLM operon and thus to the
synthesis of L-Ara4N and its transfer to lipid A (Fig. 3).
Regulators of the PmrAB and PhoPQ Two-Component Systems
The mgrB gene. MgrB (also called YobG) is a small transmembrane protein of 47
amino acids (129). Upon activation of PhoP, the mgrB gene is upregulated. The MgrB
protein in turn represses the expression of the PhoQ-encoding gene, leading to negative
regulation of the PhoPQ two-component system (Fig. 3) (129). Inactivation of the mgrB
gene (the negative regulator of the PhoPQ two-component system) leads to overexpres-
sion of the phoPQ operon, thus causing pmrHFIJKLM operon activation, leading to the
production of L-Ara4N responsible for the acquisition of colistin resistance.
Several missense mutations resulting in amino acid substitutions and nonsense
mutations and therefore leading to a truncated MgrB protein may be responsible for
acquired resistance to colistin in K. pneumoniae (Table 3). Other alterations, such as
insertions or deletions of small nucleotide sequences in the mgrB gene, or even some
complete deletions of the mgrB locus, have been reported (120, 130, 131). Insertional
inactivation caused by diverse insertion sequences (IS), belonging to several families
and inserted at different locations within the mgrB gene, is often responsible for
acquired resistance to colistin in K. pneumoniae (105, 117, 120, 130–132) and Klebsiella
oxytoca (133, 134). Recently, the transposition of genes encoding extended-spectrum
-lactamases (ESBLs) or carbapenemases, leading to disruption of the chromosomal
mgrB gene, was reported as a source of resistance to colistin (135, 136). Notably,
selective pressure with -lactams leading to the acquisition of -lactamase genes may
therefore be responsible for coselection of colistin resistance. Despite the high homol-
ogy observed among mgrB gene sequences of Enterobacteriaceae organisms (129),
disruption of this gene has so far not been found to be responsible for acquired
resistance to colistin in genera other than Klebsiella.
The crrAB operon. The crrAB (colistin resistance regulation) operon codes for two
proteins, namely, the regulatory protein CrrA and the sensor protein kinase CrrB. The
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TABLE 3 Chromosomal mutations and amino acid deletions responsible for acquired
colistin resistance in Klebsiella pneumoniae, Enterobacter aerogenes, Escherichia coli,
Salmonella enterica, P. aeruginosa, and A. baumannii isolates
Bacterial group and
species
Protein (normal
length [aa])
Domain involved
(residues)a,b
Amino acid
changed Reference(s)
Enterobacteriaceae
K. pneumoniae PmrA (223) REC (1–112) S42N 120
G53C 105, 120
G53S 105
Trans_reg_C (145–216)
PmrB (365) TM (13–35) ΔR14 118
L17Q 105
HAMP (90–142) L82R 116
S85R 120
T140P 120
HisKA (143–203) T157P 117–119
S208N 118
ΔY209 118
HATPase_c (250–358) R256G 117
PhoP (223) REC (1–112) V3F 117
L26Q 120
S86L 117
Trans_reg_C (145–220) D191Y 81
PhoQ (488) PhoQ sensor (10–189) R16C 105
L26P 117
L96P 120
D150G 117
S174N 118
HAMP (195–263) V258F 117
HisKA (267–330)
L348Q 120
HATPase_c (375–482) G385S 120
D434N 128
MgrB (47) K3* 105
L9* 120
I13* 120
A14S 120
W20R 105
L24H 130
V26* 120
M27K 105
C28F 120
C28Y 117, 120, 128, 130
C28* 105, 120
Q30* 105, 120
D31N 120
Q33* 105
F35I 120
G37S 130
C39Y 105
N42Y/K43I 105
I45T 105
W47R 105
W47* 105
*48Y 117
CrrB (353) Q10L 128, 137
TM (12–34) Y31H 137
HAMP (81–135) L94 M 128
HisKA (136–200) W140R 137
N141I 137
P151S 137
S195N 137
E. aerogenes PmrA G53S 121
E. coli PmrA (222) REC (1–112) R81Sc 125
Trans_reg_C (145–216)
PmrB (363) Δ7–12c 124
TM1 (15–37)
TM2 (69–91)
(Continued on next page)
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TABLE 3 (Continued)
Bacterial group and
species
Protein (normal
length [aa])
Domain involved
(residues)a,b
Amino acid
changed Reference(s)
HAMP (92–144)
HisKA (145–205) T156Kc 124
A159Vc 124
V161Gc 125
HATPase_c (252–360)
PhoQ_sensor (10–189)
HAMP (195–263)
HisKA (267–330)
PhoP (223) REC (1–112)
Trans_reg_C (145–220)
PhoQ (486) PhoQ_sensor (10–189)
HAMP (195–263)
HisKA (267–330)
HATPase_c (374–480) E375Kc 65
S. enterica PmrA (222) REC (1–112) G15Rc 123
G53Ec 123
G53Rc 123
R81Cc 123
R81Hc 123
Trans_reg_C (145–216)
PmrB (356) TM (13–35) Δ11–14c 122
L14Fc 123
L14Sc 123
M15Lc 122
L22Pc 123
S29Rc 123
HAMP (89–141) T92Ac 123
P94Qc 123
E121Ac 123
S124Pc 123
N130Yc 123
HisKA (142–202) T147Pc 123
R155Pc 123
T156Mc 123
T156Pc 123
V161Gc 123
V161Lc 123
V161Mc 123
E166Kc 123
M186Ic 123
HATPase_c (249–356) G206Rc 123
G206Wc 123
S305Rc 123
Nonfermentative
bacilli
P. aeruginosa PmrA (221) REC (1–112)
Trans_reg_C (145–216) L157Q 166
PmrB (477) L14P 167
TM1 (15–37)
PD (38–160) ΔD45 74, 167
A54V 167
TM2 (161–183) L167P 166
HAMP (186–238) G188D 167
F237L 118
HisKA (239–304) L243Q 167
A247T 168
A248V 167
S257N 167
M292I 167
M292T 169
HATPase_c (348–459)
PhoQ (448) R6C 170
TM1 (7–29)
(Continued on next page)
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TABLE 3 (Continued)
Bacterial group and
species
Protein (normal
length [aa])
Domain involved
(residues)a,b
Amino acid
changed Reference(s)
ΔV57–Q332 170
PD (30–166) N104I 118
K123Q 166
K123E 118
Q133E 118
A143V 166
V152* 168
TM2 (167–189) V184G 118
A207R 118
R214H 118
H223R 168
HisKA (238–300) V260G 163, 247
HATPase_c (343–448) ΔL364–G365 170
I421* 170
Fr at I421 170
D433* 170
R444C 170
ParR (235) REC (7–117) L18I 118
N24S 118
S24N 118
M59I 171
Trans_reg_C (152–228) E156K 171
ParS (428) TM1 (5–27) L14Q 171
PD (28–131) V101 M 171
TM2 (132–154) L137P 171
HAMP (155–207)
HisKA (208–273) Q232E 118
HATPase_c (318–428) G361R 118
H398R 247
ColS A106V 172
CprS R241C 172
A. baumannii PmrA (224) REC (2–112) E8D 177, 180
M12I 174
P102H 173
S119T 174
Trans_reg_C (150–221)
PmrB (444) TM1 (10–29) T13N 173
S14L 175
S17R 177
Fr at F26 176
PD (30–141) ΔA32–E35 174
D64V 174
A80V 174
L87F 175
Y116H 177
I121F 178
TM2 (142–164) M145K 175
ΔL160 174
P170L 174, 179
P170Q 174
A183T 178
A184V 178
P190S 178
T192I 178
L208F 174
HisKA (218–280) A226V 174
A227V 173, 175, 176
Q228P 178
R231L 174
T232I 177
P233S 118, 173–176, 179
P233T 173
T235I 174
N256I 174
(Continued on next page)
577
physiological role of the crrAB operon is still unknown. However, inactivation of the crrB
gene leads to overexpression of the pmrAB operon, thus causing activation of the
pmrHFIJKLM operon and of the pmrC and pmrE genes, consequently leading to the
production of L-Ara4N and pEtN, both of which are responsible for the acquisition of
colistin resistance (Fig. 3) (128). CrrB inactivation may also modify lipid A through
activation of a glycosyltransferase-like protein (128).
Six amino acid substitutions in the CrrB protein have been identiﬁed as being
responsible for acquired resistance to polymyxins in K. pneumoniae (Table 3) (128, 137).
The Intrinsic Regulator RamA
The intrinsic regulator RamA of K. pneumoniae is known to play a signiﬁcant role in
the overall response to antimicrobials. It regulates genes that are linked to permeability
barriers and therefore may be involved in reduced susceptibility to antibiotics. It was
recently shown that increased levels of this regulator caused LPS alterations and
consequently reduced susceptibility to polymyxins (138).
Plasmid-Mediated Resistance to Polymyxins
The plasmid-mediated mcr-1 gene, responsible for horizontal transfer of colistin
resistance, was described ﬁrst for E. coli and K. pneumoniae isolates recovered in China
between 2011 and 2014 (139). The encoded MCR-1 protein is a member of the
phosphoethanolamine transferase enzyme family, as its acquisition results in the
addition of phosphoethanolamine to lipid A, and consequently in a more cationic LPS,
similarly to the chromosomal mutations mentioned above.
Overall, production of MCR-1 in E. coli leads to 4- to 8-fold increases of the MICs of
polymyxins. Therefore, without additional resistance mechanisms, production of MCR-1 is
enough to confer resistance to colistin in E. coli and other enterobacterial species, such as
TABLE 3 (Continued)
Bacterial group and
species
Protein (normal
length [aa])
Domain involved
(residues)a,b
Amino acid
changed Reference(s)
A262P 173
R263C 174
R263L 177
R263P 174
Q277H 174
G315D 174
HATPase_c (326–437) N353Y 175
P377L 174
F387Y 175
S403F 175
LpxA (262) Fr at I25 109
G68D 109
Q72K 109
Fr at H121 109
Fr at D130 109
H159D 109
Q234* 109
LpxC (276) P30L 109
Fr at D45 109
Fr at T285 109
LpxD (356) Fr at K317 109
aDomains predicted in SMART by using protein sequences of Escherichia coli K-12 substrain MG1655,
Klebsiella pneumoniae subsp. pneumoniae MGH 78578, Salmonella enterica serovar Typhimurium LT2, P.
aeruginosa PAO1, and A. baumannii AB0057. REC, CheY-homologous receiver domain; Trans_reg_C,
transcriptional regulatory protein, C-terminal domain; TM, transmembrane domain; TM1, ﬁrst
transmembrane domain; TM2, second transmembrane domain; PD, periplasmic domain; HAMP, histidine
kinases, adenylyl cyclases, methyl-binding proteins, and phosphatases; HisKA, histidine kinase A
(phosphoacceptor) domain; HATPase_c, histidine kinase-like ATPases; PhoQ sensor, phosphorelay signal
transduction system.
bA periplasmic domain (PD) was not predicted in SMART but was assumed to be between TM1 and TM2.
cThe involvement of the mutation in the colistin resistance proﬁle was determined by in silico analysis.
dΔ, deletion; Fr, frameshift; *, stop codon.
578
K. pneumoniae (our unpublished data). Note that despite the fact that polymyxins actually
share the same mechanism of action as that of the cationic antimicrobial peptides (CAMPs)
cathelicidin LL-37, -defensin 5 (HD5), and -defensin 3 (HDB3), which are normal compo-
nents of the immune system, coresistance to CAMPs and polymyxins has not beeen
observed (J. Dobias, L. Poirel, and P. Nordmann, submitted for publication).
Apart from resistance to polymyxin antibiotics, production of MCR-1 was shown to
confer resistance to lysozyme (140). The structure of MCR-1 was recently solved at a
1.32-Å resolution, revealing that its active site is similar to that of related phosphoe-
thanolamine transferases (141). Threonine 285 was identiﬁed as the putative nucleo-
phile for catalysis, as it was phosphorylated in the catalytic domain of MCR-1 (cMCR-1).
Four zinc ions were identiﬁed in the active site of cMCR-1, which is thus a metalloen-
zyme. The binding sites for the lipid A and phosphatidylethanolamine substrates were
not apparent in the cMCR-1 structure, likely indicating that they were present in the
membrane domain.
Following these initial ﬁndings, themcr-1 gene was reported worldwide and beyond
China, on all continents (Fig. 4; Table 4). The earliest mcr-1-positive strain was collected
from chickens in China 3 decades ago (142), when colistin ﬁrst started to be used in
food-producing animals. The mcr-1 gene has been found in various genera of the
Enterobacteriaceae (Escherichia, Klebsiella, Enterobacter, Cronobacter, Salmonella, Shi-
gella, and Kluyvera) isolated from the environment, vegetable and meat foods, animals,
and human beings (Fig. 4; Table 4). Note that the occurrence of MCR-1-producing E. coli
in the environment in Switzerland but also in Asian imported vegetables in the same
country highlights the likely wide occurrence of that resistance trait in many different
environments (143).
The hypothesis that animals, particularly pigs and cattle, might be a main source of
MCR-1 producers is very strong. Indeed, several features are in accordance with such a
hypothesis, including the high selective pressure in veterinary practice and the wide
occurrence of that resistance trait in isolates recovered from animals (144).
The genetics of acquisition of themcr-1 gene has been investigated extensively. This
gene was found in plasmids possessing various backbones (IncI2, IncHI2, IncP, IncX4,
IncFI, and IncFIB) and of various sizes (58 to 251 kb). Upstream of the mcr-1 gene, the
ISApl1 insertion sequence element is inconstantly identiﬁed (Table 4) (139). Thanh et al.
(145) described an mcr-1 gene disrupted by a 22-bp duplication in a Shigella sonnei
isolate. This isolate was colistin susceptible, but under selective pressure with colistin,
one copy of the 22-bp tandem repeat could be deleted, restoring the open reading
frame ofmcr-1 and leading to colistin resistance. This deactivated version of the colistin
resistance gene mcr-1 suggests a ﬁtness cost for the active mcr-1 gene. Some but not
all plasmids bearing the mcr-1 gene carry other antimicrobial resistance genes encod-
ing resistance to clinically relevant antibiotics for human medicine, such as -lactams,
aminoglycosides, quinolones, fosfomycin, sulfonamides, and tetracyclines. The location
of the mcr-1 gene on multidrug resistance plasmids is worrying because the use of
antimicrobials other than polymyxins can participate in the coselection of isolates
carrying mcr-1 and in their spread. More worryingly, the plasmid-mediated mcr-1 gene
has been identiﬁed in highly drug-resistant Enterobacteriaceae isolates harboring plas-
mids encoding carbapenemase genes (blaNDM-1, blaNDM-5, blaNDM-9, blaOXA-48, blaKPC-2,
and blaVIM-1) (146–152). Note that the mcr-1 gene was recently identiﬁed on the
chromosome of an E. coli strain in Switzerland, suggesting that this resistance gene
might be integrated and therefore stabilized in the genome in some isolates (153).
Further investigations are required to better understand the process of acquisition
of the mcr-1 gene; however, we recently showed that it was located within a 2,600-bp
genetic structure, deﬁned as the “mcr-1 cassette,” that might have been mobilized by
transposition (154). The cassette was found to carry its own promoter sequences
driving the expression of mcr-1. In addition, it was shown that several isolates may
possess the mcr-1 gene located in a composite transposon structure made of two
copies of ISApl1 (155). However, that structure has not been identiﬁed systematically,
and therefore further investigations are still required to better understand the process
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of acquisition of that gene from an unknown progenitor in plasmids replicating in
Enterobacteriaceae.
MCR-1-producing enterobacterial isolates have often been identiﬁed as colonizers in
either humans or animals. Nevertheless, there are some reported cases of infections,
including two patients with bacteremia in Switzerland (156).
A functional variant of mcr-1 (Q3L) encoding MCR-1.2 was detected in KPC-3-
producing K. pneumoniae in Italy (157), likely sharing the same activity as MCR-1.
In addition, the plasmid-mediated colistin resistance gene mcr-2 was identiﬁed in E.
coli strains recovered from piglets in Belgium (158). It shared 77% nucleotide identity
with mcr-1 and was carried on an IncX4 plasmid.
Other Mechanisms Contributing to Polymyxin Resistance in Enterobacteriaceae
Hyperproduction of CPS. A study showed that the capsule polysaccharide (CPS)
acts as a protective barrier against polymyxins in K. pneumoniae (159). The upregulation
FIG 4 Reports of MCR-1-producing isolates in humans, animals, and both humans and animals.
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of capsular biosynthesis genes indeed reduces the interactions of polymyxins with the
bacterial surface, leading to polymyxin resistance.
K. pneumoniae is able to release anionic capsular polysaccharides from its surface
(160). This release leads to the trapping of cationic antimicrobial peptides, such as
polymyxins, thus decreasing the amount of antibiotic reaching the bacterial surface.
The CPS is connected to the bacterial surface through an ionic interaction with the LPS,
and this interaction is stabilized by divalent cations (161). As a consequence, the release
of CPS in the presence of polymyxins is likely due to perturbation of the cation-
dependent bridges between the molecules of LPS.
Role of porins. It has been shown that a periplasmic protein (YdeI) regulated by the
PhoPQ and PmrAB two-component systems can interact with the OmpD porin to
increase bacterial resistance to polymyxins in Salmonella enterica (162).
Role of efﬂux pumps. The role of efﬂux in colistin resistance is not well understood,
but several studies suggested the involvement of efﬂux pumps in colistin resistance.
Mutations in kpnEF and acrAB, encoding components of efﬂux pumps, may actually
lead to a 2-fold decrease of the MIC of colistin and increase bacterial survival in the
presence of a low concentration of polymyxins (163, 164). Addition to the test medium
of low doses of the efﬂux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone
(CCCP) decreased the MICs for resistant strains (128- to 512-fold reductions) and
partially or completely inhibited the regrowth of resistant subpopulations (165). How-
ever, this observation should be considered with caution owing to the nonspeciﬁc
effect of CCCP on efﬂux systems, with a likely wider impact on bacterial metabolism.
Mechanisms of Polymyxin Resistance in Pseudomonas aeruginosa and Acinetobac-
ter baumannii
Pseudomonas aeruginosa. The colistin resistance in P. aeruginosa is mediated by ﬁve
two-component systems that regulate LPS modiﬁcations. As for the Enterobacteriaceae,
alterations in the PmrAB (74, 118, 166–169) and PhoPQ (118, 166, 168, 170) two-
component systems have been shown to be responsible for acquired resistance to
colistin. Mutations in these two-component systems cause constitutive alterations and
consequently activate transcription of the pmrHFIJKLM operon and the subsequent
addition of L-Ara4N to the LPS, ﬁnally leading to colistin resistance. Notably, unlike what
is observed in K. pneumoniae, the colistin resistance mediated by PhoPQ modiﬁcations
does not depend on the PmrAB system.
Three other two-component systems have been proved to contribute to colistin
resistance in P. aeruginosa, namely, ParRS, ColRS, and CprRS. The ParRS (polymyxin
adaptive resistance) two-component system is involved in adaptative resistance to
polymyxins (118, 166, 171). Mutations in this system cause constitutive expression of
the pmrHFIJKLM operon and thus lead to the addition of L-Ara4N to the LPS, leading to
colistin resistance. Additionally, mutations in the ColRS and CprRS two-component
regulatory systems may also contribute to polymyxin resistance, since the association
of mutations in the phoQ gene and mutations in the colS or cprS gene confers a high
level of colistin resistance (172). The action of the ColRS and CprRS systems may occur
through the activation of the phoQ gene and/or through other genes that have not yet
been identiﬁed.
Acinetobacter baumannii. The main mechanism of colistin resistance in A. bauman-
nii corresponds to the addition of cationic groups to the LPS (qualitative modiﬁcation
of the LPS); nevertheless, acquired resistance to colistin may also be the consequence
of a complete loss of LPS production (quantitative modiﬁcation of the LPS).
The addition of cationic groups in A. baumannii is mediated by mutations in PmrAB
(118, 173–180). Mutations in the pmrA and pmrB genes have been shown to cause
colistin resistance through upregulation of the pmrCAB operon, leading to pEtN syn-
thesis but not to L-Ara4N synthesis (unlike in Enterobacteriaceae).
The second mechanism of colistin resistance in A. baumannii corresponds to the
complete loss of LPS caused by alterations of the lipid A biosynthesis genes, namely,
the lpxA, lpxC, and lpxD genes. Mutations identiﬁed in those genes were either
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substitutions, truncations, frameshifts (109), or insertional inactivation by the insertion
sequence ISAba11 (181).
EPIDEMIOLOGY OF RESISTANCE TO POLYMYXINS
General Epidemiology of Resistance to Polymyxins
Although polymyxins currently retain signiﬁcant in vitro activity against most Gram-
negative organisms, resistance to these antibiotics is increasingly being reported
among clinical isolates (29, 182).
The SENTRY antimicrobial surveillance program carried out a worldwide survey in
2009 and reported low rates of resistance to polymyxins among Gram-negative patho-
gens (Acinetobacter spp., P. aeruginosa, E. coli, and Klebsiella spp.) (0.1% to 1.5%) (183).
However, a rising trend was observed in a 2006-2009 study period focusing on K.
pneumoniae isolates (resistance rates of 1.2% in 2006 and 1.8% in 2009), probably
because of the extensive and/or inadequate usage of polymyxins worldwide for
treating infections with MDR Gram-negative bacteria.
Colistin resistance in K. pneumoniae represents a growing public health concern,
since this bacterial species is one of the main pathogens of nosocomial infection and
has gathered a wide range of resistance mechanisms to broad-spectrum antibiotics
over the years. Table 5 shows the populations studied (mainly carbapenem-resistant K.
pneumoniae [CR-KP] clinical isolates), along with the methods that have been used to
determine the rate of colistin resistance, since some methods are now known to
underestimate the level of colistin resistance and therefore may signiﬁcantly bias the
proposed rates. The occurrence of colistin resistance in K. pneumoniae has been
reported in surveillance studies and clinical case reports worldwide (Table 5) (183).
Many studies report an increase of the resistance rate among multidrug-resistant K.
pneumoniae isolates, particularly among CR-KP isolates, with high colistin resistance
rates reported (Table 5). More worryingly, multiple outbreaks with carbapenem- and
colistin-resistant isolates have been reported in North America and Europe (Table 6;
Fig. 5).
North America. Multicenter surveys showed low rates of resistance among K. pneu-
moniae isolates in Canada (2.9%) (184) and the United States (4%) (185) (Table 5). However,
the colistin resistance rate was higher (6.7 to 18%) among carbapenemase-producing
isolates (185–187). In addition, outbreaks with colistin-resistant, KPC-producing K. pneu-
moniae, mostly attributed to the international epidemic clone type ST258, have been
reported in the United States (188, 189) and Mexico (190) (Table 6; Fig. 5).
South America. The results from the SENTRY antimicrobial surveillance program
showed a moderate resistance rate in Latin America in 2009 (3%) (183); however, the
emergence of colistin-resistant K. pneumoniae isolates has been reported in Argentina
(191), Colombia (119), and Brazil (87).
Europe. Multiple outbreaks of both carbapenem- and colistin-resistant K. pneu-
moniae isolates have been reported in Europe (Table 6; Fig. 5). Outbreaks with KPC-
producing K. pneumoniae isolates attributed to the international epidemic clone type
ST258 have been reported in the Netherlands (192), Hungary (193), Greece (194, 195),
and Italy (196, 197).
In addition to the two outbreaks attributed to the ST258 clone (196, 197), a large
nosocomial outbreak of colistin-resistant and KPC-producing ST512 K. pneumoniae
isolates was reported in Italy (198) (Table 6; Fig. 5). More worryingly, colistin resistance
was recently reported at a high level (20%) among carbapenemase-producing iso-
lates in ICUs of two Italian hospitals (199, 200), with an even higher rate (36.1%) in
hospitals in Rome (68) (Table 6). Moreover, a national study reported a countrywide
level of colistin resistance among KPC-producing K. pneumoniae isolates, with 43% of
isolates being resistant to colistin (201) (Table 5).
In Greece, several outbreaks caused by KPC-producing, colistin-resistant K. pneu-
moniae isolates have been reported (194, 195) (Table 6; Fig. 5). Studies performed in
two Greek hospitals reported a huge increase in colistin resistance within a few years
(3.5% incidence before 2010 and 20% incidence after 2010) (202, 203).
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During a 2-year period (2010 to 2012) in Spain, a study showed an increase of the
prevalence of colistin resistance among carbapenemase-producing K. pneumoniae
isolates, from 13.5 to 31.7%, and an outbreak of colistin-resistant, VIM-1-producing K.
pneumoniae was reported (204).
In France, a national survey revealed a low rate of colistin resistance (6.2%) among
carbapenemase-producing K. pneumoniae isolates; neverthess, an outbreak of OXA-48
carbapenemase-producing and colistin-resistant K. pneumoniae isolates was reported
(205).
Middle East. In Turkey and Israel, low rates of resistance to colistin among CR-KP
isolates have been reported (2.7% and 4.5%, respectively). However, multiclonal out-
breaks with OXA-48-, NDM-, and both OXA-48- and NDM-producing K. pneumoniae are
currently ongoing in Turkey (our unpublished data).
Africa. A very low colistin resistance rate was reported among K. pneumoniae
isolates in Tunisia (1.2%), but this rate was probably underestimated because suscep-
tibility to colistin was primarily screened using a DD method generating high false
susceptibility rates (205). The emergence of colistin resistance was reported for K.
pneumoniae isolates recovered in South Africa (81, 119) and Nigeria (120).
Asia. Moderate rates of colistin resistance (about 6 to 11%) have been reported for
K. pneumoniae isolates from South Korea (206) and Singapore (207), and similar
resistance rates (4.4 to 12.1%) were found among CR-KP isolates in China (208) and
Taiwan (209). Colistin-resistant K. pneumoniae isolates have also been reported in Laos
and Thailand (120).
Risk Factors
The use of colistin was found to be an independent risk factor for the occurrence of
resistance in Gram-negative bacteria (210, 211). Important increases of colistin resis-
tance rates among ESBL-producing K. pneumoniae isolates (from 0 to 71% and from
11.1 to 75%) were reported after the introduction of selective digestive tract decon-
tamination in two intensive care units (212, 213). Moreover, this decontamination failed
to prevent colonization by ESBL-producing Enterobacteriaceae, and such a strategy
should be abandoned. Note that the inappropriate use of colistin (such as suboptimal
dosing or prolonged monotherapy) has been shown to be a source of colistin resistance
selection (214, 215). The occurrence of colistin resistance in P. aeruginosa was most
FIG 5 Outbreaks caused by colistin-resistant, carbapenemase-producing K. pneumoniae isolates. Each star
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effectively prevented by 8-h dosing intervals compared to 12- or 24-h dosing intervals
(45).
Speciﬁc Epidemiology of the Plasmid-Mediated mcr-1 Resistance Gene
Notably, plasmid-borne resistance to polymyxins has been reported for few different
enterobacterial species so far, mainly among E. coli isolates and rarely for Salmonella
enterica, Enterobacter spp., and K. pneumoniae. There are also some scattered reports of
MCR-1-producing isolates in other species, such as Cronobacter sakazakii (152) and
Kluyvera ascorbata (216). According to the current literature on the subject, the
distribution of MCR-1 appears to be worldwide, covering all continents (217). It remains
to be determined if the identiﬁcation of the mcr-1 gene worldwide corresponds to
subsequent spread from an original source (China?) or to simultaneous gene mobili-
zation events in different parts of the world. Ongoing epidemiological surveys should
provide some important clues.
It is actually speculated that the original source of the gene, or at least of its
mobilization and emergence, might be the animal world. This speculation is based on
the fact that MCR-1-producing E. coli isolates have been identiﬁed in several animals
and animal food products, including chickens and chicken meat, pigs and piglets,
cattle, calves, and turkeys, but also in humans (Fig. 4). The corresponding samples were
collected from many Asian countries (Cambodia, China, Japan, Laos, Malaysia, Taiwan,
Singapore, and Vietnam) but also from Europe (Belgium, Denmark, France, Germany,
Portugal, Italy, the Netherlands, Spain, Sweden, Switzerland, and the UK), the Americas
(Argentina, Brazil, and Canada), and Africa (Algeria, Egypt, South Africa, and Tunisia)
(Table 4). Note that a study conducted in Switzerland identiﬁed MCR-1-producing E. coli
isolates in vegetables imported from Asia (143), and positive isolates were also iden-
tiﬁed in environmental water samples in Switzerland and Malaysia (Table 4).
The speculation of an animal origin of the mcr-1 gene is also based on genetic
features, since this gene is often associated with the insertion sequence ISApl1, iden-
tiﬁed in Pasteurella multocida, which is a common animal pathogen, and also with the
blaCMY-2 and ﬂorR genes, which are often identiﬁed in animal enterobacterial isolates
(144). Finally, another feature suggesting an animal source of the problem is the heavy
usage of polymyxins in veterinary medicine, with usage on many different animal
species.
Dating the emergence of MCR-1-positive strains remains quite difﬁcult; however, a
Chinese study retrospectively identiﬁed positive isolates recovered from chickens
during the 1980s (142), and they were discovered as early as 2005 in veal calves in
France (144). It therefore seems that the emergence of MCR-positive isolates, at least in
animals, is not a recent event. Very likely, there has been some silent dissemination of
that resistance mechanism throughout the last few decades, and the current situation
shows an ongoing further dissemination rather than an emerging phenomenon.
CONCLUSIONS
Polymyxins are gaining increasing interest because of the current epidemiological
situation, with MDR Gram-negative bacteria spreading worldwide and with a paucity of
novel marketed antibiotics. In some areas where infections caused by carbapenem-
resistant Enterobacteriaceae are now common (such as Greece or Italy), the use of
polymyxins (alone or often in combination with other antibiotics) is becoming crucial
and may even be considered ﬁrst-line therapy. The reevaluation of some critical issues
in relation to polymyxins (accurate susceptibility testing, deﬁning correct breakpoints,
and better appreciating the toxicity issues) now opens new perspectives for its use.
Studies that may permit a better evaluation of the PK-PD data, the toxicity level, and
appropriate drug combinations are therefore crucial.
The recent identiﬁcation of plasmid-mediated mechanisms of resistance to poly-
myxins also modiﬁes the perspective. Indeed, epidemiological studies have to be
initiated in order to better evaluate the extent of dissemination of this resistance in
human and veterinary medicine and the impact of its occurrence. The perspective of
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nosocomial dissemination of MDR Gram-negative organisms possessing resistance
determinants to all main antibiotics is frightening, in particular for K. pneumoniae,
which is one of the main nosocomial pathogens. Whether veterinary medicine is
affecting the epidemiological situation by providing selective pressure with polymyxins
has to be precisely determined. Whether discontinuing some speciﬁc usages of these
drugs (prophylaxis or metaphylaxis in animals and decontamination of MDR bacteria in
humans) should be considered is therefore an open debate.
Ultimately, reinforcing the detection of polymyxin-resistant isolates must be encour-
aged. Prospective epidemiological surveys are needed, since the current knowledge on
this issue is very scarce. Actually, the recent development of a rapid diagnostic test for
detection of polymyxin resistance, along with the development of a screening agar
medium, will contribute to facilitating those surveys.
ACKNOWLEDGMENTS
This work was funded by the University of Fribourg, Switzerland, and by a grant from
the ANIWHA ERA-NET project, Switzerland (ANIWHA).
REFERENCES
1. Benedict RG, Langlykke AF. 1947. Antibiotic activity of Bacillus poly-
myxa. J Bacteriol 54:24.
2. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418–422. https://
doi.org/10.1016/S0140-6736(97)80051-7.
3. Falagas ME, Rafailidis PI, Matthaiou DK. 2010. Resistance to polymyxins:
mechanisms, frequency and treatment options. Drug Resist Updat
13:132–138. https://doi.org/10.1016/j.drup.2010.05.002.
4. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson
DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant
Gram-negative bacterial infections. Lancet Infect Dis 6:589–601.
https://doi.org/10.1016/S1473-3099(06)70580-1.
5. Brink AJ, Richards GA, Colombo G, Bortolotti F, Colombo P, Jehl F. 2014.
Multicomponent antibiotic substances produced by fermentation: im-
plications for regulatory authorities, critically ill patients and generics.
Int J Antimicrob Agents 43:1–6. https://doi.org/10.1016/j.ijantimicag
.2013.06.013.
6. Gallardo-Godoy A, Muldoon C, Becker B, Elliott AG, Lash LH, Huang JX,
Butler MS, Pelingon R, Kavanagh AM, Ramu S, Phetsang W, Blaskovich
MA, Cooper MA. 2016. Activity and predicted nephrotoxicity of syn-
thetic antibiotics based on polymyxin B. J Med Chem 59:1068–1077.
https://doi.org/10.1021/acs.jmedchem.5b01593.
7. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod,
or chalk and cheese? Clin Infect Dis 59:88–94. https://doi.org/10.1093/
cid/ciu213.
8. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate
is an inactive prodrug of colistin against Pseudomonas aeruginosa.
Antimicrob Agents Chemother 50:1953–1958. https://doi.org/10.1128/
AAC.00035-06.
9. Barnett M, Bushby SR, Wilkinson S. 1964. Sodium sulphomethyl deriv-
atives of polymyxins. Br J Pharmacol Chemother 23:552–574. https://
doi.org/10.1111/j.1476-5381.1964.tb01610.x.
10. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. 2003. Stability of
colistin and colistin methanesulfonate in aqueous media and plasma as
determined by high-performance liquid chromatography. Antimicrob
Agents Chemother 47:1364–1370. https://doi.org/10.1128/AAC.47.4
.1364-1370.2003.
11. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2004.
Pharmacokinetics of colistin methanesulphonate and colistin in rats
following an intravenous dose of colistin methanesulphonate. J Anti-
microb Chemother 53:837–840. https://doi.org/10.1093/jac/dkh167.
12. Dixon RA, Chopra I. 1986. Leakage of periplasmic proteins from Esch-
erichia coli mediated by polymyxin B nonapeptide. Antimicrob Agents
Chemother 29:781–788. https://doi.org/10.1128/AAC.29.5.781.
13. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for
the management of multidrug-resistant Gram-negative bacterial infec-
tions. Clin Infect Dis 40:1333–1341. https://doi.org/10.1086/429323.
14. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of
colistin as an agent against multi-resistant Gram-negative bacteria. Int
J Antimicrob Agents 25:11–25. https://doi.org/10.1016/j.ijantimicag
.2004.10.001.
15. Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE, Nation RL, Li
J, Velkov T. 2013. A secondary mode of action of polymyxins against
Gram-negative bacteria involves the inhibition of NADH-quinone oxi-
doreductase activity. J Antibiot (Tokyo) 67:147–151. https://doi.org/
10.1038/ja.2013.111.
16. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D’Hondt RE, Jusko WJ,
Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high
inoculum of Pseudomonas aeruginosa characterized by a newmechanism-
based population pharmacodynamic model. Antimicrob Agents Che-
mother 54:2051–2062. https://doi.org/10.1128/AAC.00881-09.
17. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics
of colistin against Acinetobacter baumannii clinical isolates. J Antimi-
crob Chemother 59:473–477. https://doi.org/10.1093/jac/dkl512.
18. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation
RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-
resistant Klebsiella pneumoniae. J Antimicrob Chemother 62:
1311–1318. https://doi.org/10.1093/jac/dkn425.
19. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J.
2012. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins:
what is new? Diagn Microbiol Infect Dis 74:213–223. https://doi.org/
10.1016/j.diagmicrobio.2012.07.010.
20. Cheah SE, Wang J, Nguyen VTT, Turnidge JD, Li J, Nation RL. 2015. New
pharmacokinetic/pharmacodynamic studies of systemically adminis-
tered colistin against Pseudomonas aeruginosa and Acinetobacter bau-
mannii in mouse thigh and lung infection models: smaller response in
lung infection. J Antimicrob Chemother 70:3291–3297. https://doi.org/
10.1093/jac/dkv267.
21. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J,
Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of
colistin methanesulfonate and formed colistin in critically ill patients
from a multicenter study provide dosing suggestions for various cate-
gories of patients. Antimicrob Agents Chemother 55:3284–3294.
https://doi.org/10.1128/AAC.01733-10.
22. Landersdorfer CB, Nation RL. 2015. Colistin: how should it be dosed for
the critically ill? Semin Respir Crit Care Med 36:126–135. https://
doi.org/10.1055/s-0034-1398390.
23. Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin—back to basic
PK/PD. Curr Opin Pharmacol 11:464–469. https://doi.org/10.1016/j
.coph.2011.07.004.
24. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer
JC. 2003. Synergistic activity of colistin and ceftazidime against
multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro phar-
macodynamic model. Antimicrob Agents Chemother 47:905–909.
https://doi.org/10.1128/AAC.47.3.905-909.2003.
25. John EB, Bennett RD, Blaser MJ. 2015. Polymyxins (polymyxin B and
colistin), p 549–555. In Bennett JE, Dolin R, Blaser MJ (ed), Mandell,
589
Douglas, and Bennett’s principles and practice of infectious diseases,
8th ed. Elsevier/Saunders, Philadelphia, PA.
26. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006.
Heteroresistance to colistin in multidrug-resistant Acinetobacter bau-
mannii. Antimicrob Agents Chemother 50:2946–2950. https://doi.org/
10.1128/AAC.00103-06.
27. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, Nation RL, Li
J. 2009. Colistin hetero-resistance in multidrug-resistant Acinetobacter
baumannii clinical isolates from the Western Paciﬁc region in the
SENTRY antimicrobial surveillance programme. J Infect 58:138–144.
https://doi.org/10.1016/j.jinf.2008.11.002.
28. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Soﬁanou D. 2011. Colistin
heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J
Antimicrob Chemother 66:946–947. https://doi.org/10.1093/jac/dkr007.
29. Bialvaei AZ, Samadi Kaﬁl H. 2015. Colistin, mechanisms and prevalence
of resistance. Curr Med Res Opin 31:707–721. https://doi.org/10.1185/
03007995.2015.1018989.
30. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE.
1970. Adverse effects of sodium colistimethate. Manifestations and
speciﬁc reaction rates during 317 courses of therapy. Ann Intern Med
72:857–868.
31. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG,
Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL,
Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL.
2012. Multidrug-resistant, extensively drug-resistant and pandrug-
resistant bacteria: an international expert proposal for interim standard
deﬁnitions for acquired resistance. Clin Microbiol Infect 18:268–281.
https://doi.org/10.1111/j.1469-0691.2011.03570.x.
32. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012.
Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti
Infect Ther 10:917–934. https://doi.org/10.1586/eri.12.78.
33. Yahav D, Farbman L, Leibovici L, Paul M. 2012. Colistin: new lessons on
an old antibiotic. Clin Microbiol Infect 18:18–29. https://doi.org/
10.1111/j.1469-0691.2011.03734.x.
34. Ortwine JK, Kaye KS, Li J, Pogue JM. 2015. Colistin: understanding and
applying recent pharmacokinetic advances. Pharmacotherapy 35:
11–16. https://doi.org/10.1002/phar.1484.
35. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW,
Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2014.
Consistent global approach on reporting of colistin doses to promote
safe and effective use. Clin Infect Dis 58:139–141. https://doi.org/
10.1093/cid/cit680.
36. Theuretzbacher U. 2014. Product information for parenteral colistin
varies substantially across Europe. J Antimicrob Chemother 69:
1987–1992. https://doi.org/10.1093/jac/dku064.
37. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of
colistin methanesulfonate in pharmaceutical products and solutions for
administration to patients. Antimicrob Agents Chemother 52:
3047–3051. https://doi.org/10.1128/AAC.00103-08.
38. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001.
A simple method for the assay of colistin in human plasma, using
pre-column derivatization with 9-ﬂuorenylmethyl chloroformate in
solid-phase extraction cartridges and reversed-phase high-
performance liquid chromatography. J Chromatogr B Biomed Sci Appl
761:167–175. https://doi.org/10.1016/S0378-4347(01)00326-7.
39. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002.
Simple method for assaying colistin methanesulfonate in plasma and
urine using high-performance liquid chromatography. Antimicrob
Agents Chemother 46:3304–3307. https://doi.org/10.1128/AAC.46.10
.3304-3307.2002.
40. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003.
Use of high-performance liquid chromatography to study the pharma-
cokinetics of colistin sulfate in rats following intravenous administra-
tion. Antimicrob Agents Chemother 47:1766–1770. https://doi.org/
10.1128/AAC.47.5.1766-1770.2003.
41. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jans-
son B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis
A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin
methanesulfonate in critically ill patients: population pharmacokinetics,
protein binding, and prediction of bacterial kill. Antimicrob Agents
Chemother 56:4241–4249. https://doi.org/10.1128/AAC.06426-11.
42. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karat-
zas S, Rafailidis P, Apostolakos H, Baltopoulos G. 2008. Colistin serum
concentrations after intravenous administration in critically ill patients
with serious multidrug-resistant, Gram-negative bacilli infections: a
prospective, open-label, uncontrolled study. Clin Ther 30:143–151.
https://doi.org/10.1016/j.clinthera.2008.01.015.
43. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou
A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A,
Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of
colistin methanesulfonate and colistin after intravenous administration
in critically ill patients with infections caused by Gram-negative bacte-
ria. Antimicrob Agents Chemother 53:3430–3436. https://doi.org/
10.1128/AAC.01361-08.
44. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood
G, Simon D, Peters C, Ahsan M, Chateau D. 2009. Initiation of inappro-
priate antimicrobial therapy results in a ﬁvefold reduction of survival in
human septic shock. Chest 136:1237–1248. https://doi.org/10.1378/
chest.09-0087.
45. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. 2008.
Comparison of once-, twice- and thrice-daily dosing of colistin on
antibacterial effect and emergence of resistance: studies with Pseu-
domonas aeruginosa in an in vitro pharmacodynamic model. J Antimi-
crob Chemother 61:636–642. https://doi.org/10.1093/jac/dkm511.
46. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci
DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki
AP. 2013. Population pharmacokinetics of intravenous polymyxin B in
critically ill patients: implications for selection of dosage regimens. Clin
Infect Dis 57:524–531. https://doi.org/10.1093/cid/cit334.
47. Vicari G, Bauer SR, Neuner EA, Lam SW. 2013. Association between
colistin dose and microbiologic outcomes in patients with multidrug-
resistant Gram-negative bacteremia. Clin Infect Dis 56:398–404.
https://doi.org/10.1093/cid/cis909.
48. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. 2010. Safety and
efﬁcacy of intravenous colistin (colistin methanesulphonate) for severe
multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob
Agents 35:297–300. https://doi.org/10.1016/j.ijantimicag.2009.11.016.
49. Michalopoulos AS, Falagas ME. 2011. Colistin: recent data on pharma-
codynamics properties and clinical efﬁcacy in critically ill patients. Ann
Intensive Care 1:30. https://doi.org/10.1186/2110-5820-1-30.
50. Roberts JA, Lipman J. 2012. Editorial commentary: closing the
loop—a colistin clinical study to conﬁrm dosing recommendations
from PK/PD modeling. Clin Infect Dis 54:1727–1729. https://doi.org/
10.1093/cid/cis311.
51. European Medicines Agency. 2014. European Medicines Agency com-
pletes review of polymyxin-based medicines: recommendations issued
for safe use in patients with serious infections resistant to standard
antibiotics. European Medicines Agency, London, United Kingdom.
52. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW,
Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR,
Theuretzbacher U, Kuti JL. 2014. Individualised antibiotic dosing for
patients who are critically ill: challenges and potential solutions. Lancet
Infect Dis 14:498–509. https://doi.org/10.1016/S1473-3099(14)70036-2.
53. Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. 2015. Association
between colistin dose and development of nephrotoxicity. Crit Care
Med 43:1187–1193. https://doi.org/10.1097/CCM.0000000000000931.
54. Dalﬁno L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S,
Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval
colistin administration in critically ill patients: is this the right dosing
strategy? A preliminary study. Clin Infect Dis 54:1720–1726. https://
doi.org/10.1093/cid/cis286.
55. Ordooei Javan A, Shokouhi S, Sahraei Z. 2015. A review on colistin
nephrotoxicity. Eur J Clin Pharmacol 71:801–810. https://doi.org/
10.1007/s00228-015-1865-4.
56. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic
review of the evidence from old and recent studies. Crit Care 10:R27.
https://doi.org/10.1186/cc3995.
57. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-
Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma
level is an independent risk factor for nephrotoxicity: a prospective
observational cohort study. BMC Infect Dis 13:380. https://doi.org/
10.1186/1471-2334-13-380.
58. Bellomo R, Kellum JA, Ronco C. 2007. Deﬁning and classifying acute
renal failure: from advocacy to consensus and validation of the RIFLE
criteria. Intensive Care Med 33:409–413. https://doi.org/10.1007/
s00134-006-0478-x.
59. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME,
Gilliam BL. 2013. Higher incidence of acute kidney injury with intrave-
590
nous colistimethate sodium compared with polymyxin B in critically ill
patients at a tertiary care medical center. Clin Infect Dis 57:1300–1303.
https://doi.org/10.1093/cid/cit453.
60. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL,
Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter
cohort study of comparative nephrotoxicity rates associated with colis-
timethate versus polymyxin B therapy. Antimicrob Agents Chemother
58:2740–2746. https://doi.org/10.1128/AAC.02476-13.
61. Catry B, Cavaleri M, Baptiste K, Grave K, Grein K, Holm A, Jukes H,
Liebana E, Navas AL, Mackay D, Magiorakos AP, Romo MA, Moulin G,
Madero CM, Pomba MC, Powell M, Pyorala S, Rantala M, Ruzauskas M,
Sanders P, Teale C, Threlfall EJ, Torneke K, van Duijkeren E, Edo JT. 2015.
Use of colistin-containing products within the European Union and
European Economic Area (EU/EEA): development of resistance in ani-
mals and possible impact on human and animal health. Int J Antimi-
crob Agents 46:297–306. https://doi.org/10.1016/j.ijantimicag
.2015.06.005.
62. Kempf I, Fleury MA, Drider D, Bruneau M, Sanders P, Chauvin C, Madec
JY, Jouy E. 2013. What do we know about resistance to colistin in
Enterobacteriaceae in avian and pig production in Europe? Int J Anti-
microb Agents 42:379 –383. https://doi.org/10.1016/j.ijantimicag
.2013.06.012.
63. Boyen F, Vangroenweghe F, Butaye P, De Graef E, Castryck F, Heylen P,
Vanrobaeys M, Haesebrouck F. 2010. Disk prediffusion is a reliable
method for testing colistin susceptibility in porcine E. coli strains. Vet
Microbiol 144:359–362. https://doi.org/10.1016/j.vetmic.2010.01.010.
64. Kieffer N, Poirel L, Nordmann P, Madec JY, Haenni M. 2015. Emergence
of colistin resistance in Klebsiella pneumoniae from veterinary medicine.
J Antimicrob Chemother 70:1265–1267. https://doi.org/10.1093/jac/
dku485.
65. Olaitan AO, Thongmalayvong B, Akkhavong K, Somphavong S, Pabori-
boune P, Khounsy S, Morand S, Rolain JM. 2015. Clonal transmission of
a colistin-resistant Escherichia coli from a domesticated pig to a human
in Laos. J Antimicrob Chemother 70:3402–3404. https://doi.org/
10.1093/jac/dkv252.
66. Walsh TR, Wu Y. 2016. China bans colistin as a feed additive for animals.
Lancet Infect Dis 16:1102–1103. https://doi.org/10.1016/S1473-3099
(16)30329-2.
67. European Medicines Agency. 26 May 2016. Updated advice on the use
of colistin products in animals within the European Union: develop-
ment of resistance and possible impact on human and animal health.
EMA/231573/2016. http://www.ema.europa.eu/docs/en_GB/document
_library/Scientiﬁc_guideline/2016/05/WC500207233.pdf. Accessed 5
September 2016.
68. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini
M, Venditti M, Bordi E, Capozzi D, Balice MP, Tarasi A, Parisi G, Lappa A,
Carattoli A, Petrosillo N. 2013. High rate of colistin resistance among
patients with carbapenem-resistant Klebsiella pneumoniae infection ac-
counts for an excess of mortality. Clin Microbiol Infect 19:E23–E30.
https://doi.org/10.1111/1469-0691.12070.
69. Landman D, Salamera J, Quale J. 2013. Irreproducible and uninterpre-
table polymyxin B MICs for Enterobacter cloacae and Enterobacter
aerogenes. J Clin Microbiol 51:4106–4111. https://doi.org/10.1128/
JCM.02129-13.
70. Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for
contemporary clinical isolates of multidrug-resistant Gram-negative
bacilli. J Clin Microbiol 51:1678 –1684. https://doi.org/10.1128/
JCM.03385-12.
71. European Committee on Antimicrobial Susceptibility Testing (EUCAST).
2014. Breakpoint tables for interpretation of MICs and zone diameters,
version 2.0. http://www.eucast.org/ﬁleadmin/src/media/PDFs/EUCAST
_ﬁles/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf.
72. Clinical and Laboratory Standards Institute (CLSI). 2014. Performance
standards for antimicrobial susceptibility testing; 24th informational
supplement. CLSI document M100-S24. Clinical and Laboratory Stan-
dards Institute, Wayne, PA.
73. Clinical and Laboratory Standards Institute (CLSI). 2012. Methods for
dilution of antimicrobial susceptibility tests for bacteria that grow
aerobically; approved standard, 9th ed. Document M07-A9. Clinical and
Laboratory Standards Institute, Wayne, PA.
74. Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE.
2009. Involvement of pmrAB and phoPQ in polymyxin B adaptation and
inducible resistance in non-cystic ﬁbrosis clinical isolates of Pseudomo-
nas aeruginosa. Antimicrob Agents Chemother 53:4345–4351. https://
doi.org/10.1128/AAC.01267-08.
75. Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, Farooque K, Sharma
V, Misra MC. 2010. Evaluation of susceptibility testing methods for
polymyxin. Int J Infect Dis 14:e596–e601. https://doi.org/10.1016/j.ijid
.2009.09.001.
76. Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen
PH. 2007. Comparative evaluation of the VITEK 2, disk diffusion, Etest,
broth microdilution, and agar dilution susceptibility testing methods
for colistin in clinical isolates, including heteroresistant Enterobacter
cloacae and Acinetobacter baumannii strains. Antimicrob Agents Che-
mother 51:3726–3730. https://doi.org/10.1128/AAC.01406-06.
77. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. 2004.
Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomo-
nas aeruginosa isolated from cystic ﬁbrosis patients. J Antimicrob Che-
mother 54:1057–1061. https://doi.org/10.1093/jac/dkh470.
78. Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor
M, Saiman L. 2010. Colistin susceptibility testing: evaluation of reliabil-
ity for cystic ﬁbrosis isolates of Pseudomonas aeruginosa and
Stenotrophomonas maltophilia. J Antimicrob Chemother 65:1416–1423.
https://doi.org/10.1093/jac/dkq131.
79. Tan TY, Ng LS. 2006. Comparison of three standardized disc suscepti-
bility testing methods for colistin. J Antimicrob Chemother 58:
864–867. https://doi.org/10.1093/jac/dkl330.
80. Maalej SM, Meziou MR, Rhimi FM, Hammami A. 2011. Comparison of
disc diffusion, Etest and agar dilution for susceptibility testing of
colistin against Enterobacteriaceae. Lett Appl Microbiol 53:546–551.
https://doi.org/10.1111/j.1472-765X.2011.03145.x.
81. Jayol A, Nordmann P, Brink A, Poirel L. 2015. Heteroresistance to colistin
in Klebsiella pneumoniae associated with alterations in the PhoPQ
regulatory system. Antimicrob Agents Chemother 59:2780–2784.
https://doi.org/10.1128/AAC.05055-14.
82. Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME, Llanos AC, Ruiz M,
Pachon J, Aznar J. 2005. Reliability of the E-test method for detection of
colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin
Microbiol 43:903–905. https://doi.org/10.1128/JCM.43.2.903-905.2005.
83. Tan TY, Ng SY. 2007. Comparison of Etest, Vitek and agar dilution for
susceptibility testing of colistin. Clin Microbiol Infect 13:541–544.
https://doi.org/10.1111/j.1469-0691.2007.01708.x.
84. Jorgensen JH, Ferraro MJ. 2009. Antimicrobial susceptibility testing: a
review of general principles and contemporary practices. Clin Infect Dis
49:1749–1755. https://doi.org/10.1086/647952.
85. Sinirtas M, Akalin H, Gedikoglu S. 2009. Investigation of colistin sensi-
tivity via three different methods in Acinetobacter baumannii isolates
with multiple antibiotic resistance. Int J Infect Dis 13:e217–e220.
https://doi.org/10.1016/j.ijid.2008.12.012.
86. Lee SY, Shin JH, Lee K, Joo MY, Park KH, Shin MG, Suh SP, Ryang DW,
Kim SH. 2013. Comparison of the Vitek 2, MicroScan, and Etest methods
with the agar dilution method in assessing colistin susceptibility of
bloodstream isolates of Acinetobacter species from a Korean university
hospital. J Clin Microbiol 51:1924–1926. https://doi.org/10.1128/
JCM.00427-13.
87. Perez LR. 2015. Evaluation of polymyxin susceptibility proﬁle among
KPC-producing Klebsiella pneumoniae using Etest and MicroScan Walk-
Away automated system. APMIS 123:951–954. https://doi.org/10.1111/
apm.12438.
88. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin
resistance: acquired and intrinsic resistance in bacteria. Front Microbiol
5:643. https://doi.org/10.3389/fmicb.2014.00643.
89. Girardello R, Bispo PJ, Yamanaka TM, Gales AC. 2012. Cation concen-
tration variability of four distinct Mueller-Hinton agar brands inﬂuences
polymyxin B susceptibility results. J Clin Microbiol 50:2414–2418.
https://doi.org/10.1128/JCM.06686-11.
90. Chen CC, Feingold DS. 1972. Locus of divalent cation inhibition of the
bactericidal action of polymyxin B. Antimicrob Agents Chemother
2:331–335. https://doi.org/10.1128/AAC.2.5.331.
91. Newton BA. 1953. Reversal of the antibacterial activity of polymyxin
by divalent cations. Nature 172:160–161. https://doi.org/10.1038/
172160a0.
92. Matzneller P, Strommer S, Osterreicher Z, Mitteregger D, Zeitlinger M.
2015. Target site antimicrobial activity of colistin might be misesti-
mated if tested in conventional growth media. Eur J Clin Microbiol
Infect Dis 34:1989–1994. https://doi.org/10.1007/s10096-015-2441-7.
93. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH.
591
2010. Variability of polymyxin B major components in commercial
formulations. Int J Antimicrob Agents 35:308–310. https://doi.org/
10.1016/j.ijantimicag.2009.11.005.
94. Humphries RM. 2015. Susceptibility testing of the polymyxins: where
are we now? Pharmacotherapy 35:22–27. https://doi.org/10.1002/
phar.1505.
95. Tam VH, Cao H, Ledesma KR, Hu M. 2011. In vitro potency of various
polymyxin B components. Antimicrob Agents Chemother 55:
4490–4491. https://doi.org/10.1128/AAC.00119-11.
96. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revis-
ited. Clin Microbiol Rev 21:449–465. https://doi.org/10.1128/CMR
.00006-08.
97. Karvanen MC, Mohamad A, Lagerback P. 2011. Colistin is extensively
lost during normal experimental conditions, abstr D-690, p 160. Abstr
51st Intersci Conf Antimicrob Agents Chemother. American Society for
Microbiology, Washington, DC.
98. Albur M, Noel A, Bowker K, Macgowan A. 2014. Colistin susceptibility
testing: time for a review. J Antimicrob Chemother 69:1432–1434.
https://doi.org/10.1093/jac/dkt503.
99. Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2012. Use of a surfactant
(polysorbate 80) to improve MIC susceptibility testing results for poly-
myxin B and colistin. Diagn Microbiol Infect Dis 74:412–414. https://
doi.org/10.1016/j.diagmicrobio.2012.08.025.
100. Brown MR, Winsley BE. 1968. Synergistic action of polysorbate 80 and
polymyxin B sulphate on Pseudomonas aeruginosa. J Gen Microbiol
50(Suppl):ix.
101. Brown MR, Geaton EM, Gilbert P. 1979. Additivity of action between
polysorbate 80 and polymyxin B towards spheroplasts of Pseudomonas
aeruginosa NCTC 6750. J Pharm Pharmacol 31:168–170. https://
doi.org/10.1111/j.2042-7158.1979.tb13463.x.
102. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Differences in
potency and categorical agreement between colistin and polymyxin
B when testing 15,377 clinical strains collected worldwide. Diagn
Microbiol Infect Dis 83:379–381. https://doi.org/10.1016/j.diagmicrobio
.2015.08.013.
103. Sautrey G, Duval RE, Chevalley A, Fontanay S, Clarot I. 2015. Capillary
electrophoresis for fast detection of heterogeneous population in
colistin-resistant Gram-negative bacteria. Electrophoresis 36:
2630–2633. https://doi.org/10.1002/elps.201500064.
104. Tamayo M, Santiso R, Otero F, Bou G, Lepe JA, McConnell MJ, Cisneros
JM, Gosalvez J, Fernandez JL. 2013. Rapid determination of colistin
resistance in clinical strains of Acinetobacter baumannii by use of the
Micromax assay. J Clin Microbiol 51:3675–3682. https://doi.org/
10.1128/JCM.01787-13.
105. Nordmann P, Jayol A, Poirel L. 2016. Rapid detection of polymyxin
resistance in Enterobacteriaceae. Emerg Infect Dis 22:1038–1043.
https://doi.org/10.3201/eid2206.151840.
106. Jayol A, Dubois V, Poirel L, Nordmann P. 2016. Rapid detection of
polymyxin-resistant Enterobacteriaceae from blood cultures. J Clin Mi-
crobiol 54:2273–2277. https://doi.org/10.1128/JCM.00918-16.
107. Nordmann P, Jayol A, Poirel L. 2016. A universal culture medium for
screening polymyxin-resistant Gram-negative isolates. J Clin Microbiol
54:1395–1399. https://doi.org/10.1128/JCM.00446-16.
108. Levine M. 1943. The effect of concentration of dyes on differentiation
of enteric bacteria on eosin-methylene-blue agar. J Bacteriol 45:
471–475.
109. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T,
Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce
JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by
complete loss of lipopolysaccharide production. Antimicrob Agents
Chemother 54:4971–4977. https://doi.org/10.1128/AAC.00834-10.
110. Bontron S, Poirel L, Nordmann P. 2016. Real-time PCR for detection of
plasmid-mediated polymyxin resistance (mcr-1) from cultured bacteria
and stools. J Antimicrob Chemother 71:2318–2320. https://doi.org/
10.1093/jac/dkw139.
111. Aquilini E, Merino S, Knirel YA, Regue M, Tomas JM. 2014. Functional
identiﬁcation of Proteus mirabilis eptC gene encoding a core lipopoly-
saccharide phosphoethanolamine transferase. Int J Mol Sci 15:
6689–6702. https://doi.org/10.3390/ijms15046689.
112. Jiang SS, Liu MC, Teng LJ, Wang WB, Hsueh PR, Liaw SJ. 2010. Proteus
mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resis-
tance, bioﬁlm formation, and urothelial cell invasion. Antimicrob Agents
Chemother 54:1564–1571. https://doi.org/10.1128/AAC.01219-09.
113. Lin QY, Tsai YL, Liu MC, Lin WC, Hsueh PR, Liaw SJ. 2014. Serratia
marcescens arn, a PhoP-regulated locus necessary for polymyxin B
resistance. Antimicrob Agents Chemother 58:5181–5190. https://
doi.org/10.1128/AAC.00013-14.
114. Gunn JS. 2008. The Salmonella PmrAB regulon: lipopolysaccharide
modiﬁcations, antimicrobial peptide resistance and more. Trends Mi-
crobiol 16:284–290. https://doi.org/10.1016/j.tim.2008.03.007.
115. Yan A, Guan Z, Raetz CR. 2007. An undecaprenyl phosphate-
aminoarabinose ﬂippase required for polymyxin resistance in Esche-
richia coli. J Biol Chem 282:36077–36089. https://doi.org/10.1074/jbc
.M706172200.
116. Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P,
D’Andrea MM, Rossolini GM. 2014. In vivo evolution to colistin resis-
tance by PmrB sensor kinase mutation in KPC-producing Klebsiella
pneumoniae is associated with low-dosage colistin treatment. Antimi-
crob Agents Chemother 58:4399–4403. https://doi.org/10.1128/AAC
.02555-14.
117. Cheng YH, Lin TL, Pan YJ, Wang YP, Lin YT, Wang JT. 2015. Colistin
resistance mechanisms in Klebsiella pneumoniae strains from Taiwan.
Antimicrob Agents Chemother 59:2909–2913. https://doi.org/10.1128/
AAC.04763-14.
118. Choi MJ, Ko KS. 2014. Mutant prevention concentrations of colistin for
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneu-
moniae clinical isolates. J Antimicrob Chemother 69:275–277. https://
doi.org/10.1093/jac/dkt315.
119. Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P. 2014.
Resistance to colistin associated with a single amino acid change in
protein PmrB among Klebsiella pneumoniae isolates of worldwide ori-
gin. Antimicrob Agents Chemother 58:4762–4766. https://doi.org/
10.1128/AAC.00084-14.
120. Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK,
Thongmalayvong B, Akkhavong K, Somphavong S, Paboriboune P,
Chaisiri K, Komalamisra C, Adelowo OO, Fagade OE, Banjo OA, Oke AJ,
Adler A, Assous MV, Morand S, Raoult D, Rolain JM. 2014. Worldwide
emergence of colistin resistance in Klebsiella pneumoniae from healthy
humans and patients in Lao PDR, Thailand, Israel, Nigeria and France
owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemi-
ological and molecular study. Int J Antimicrob Agents 44:500–507.
https://doi.org/10.1016/j.ijantimicag.2014.07.020.
121. Diene SM, Merhej V, Henry M, El Filali A, Roux V, Robert C, Azza S,
Gavory F, Barbe V, La Scola B, Raoult D, Rolain JM. 2013. The rhizome
of the multidrug-resistant Enterobacter aerogenes genome reveals how
new “killer bugs” are created because of a sympatric lifestyle. Mol Biol
Evol 30:369–383. https://doi.org/10.1093/molbev/mss236.
122. Olaitan AO, Dia NM, Gautret P, Benkouiten S, Belhouchat K, Drali T,
Parola P, Brouqui P, Memish Z, Raoult D, Rolain JM. 2015. Acquisition
of extended-spectrum cephalosporin- and colistin-resistant Salmonella
enterica subsp. enterica serotype Newport by pilgrims during Hajj. Int
J Antimicrob Agents 45:600 – 604. https://doi.org/10.1016/j
.ijantimicag.2015.01.010.
123. Sun S, Negrea A, Rhen M, Andersson DI. 2009. Genetic analysis of
colistin resistance in Salmonella enterica serovar Typhimurium. Antimi-
crob Agents Chemother 53:2298 –2305. https://doi.org/10.1128/
AAC.01016-08.
124. Olaitan AO, Morand S, Rolain JM. 2016. Emergence of colistin-resistant
bacteria in humans without colistin usage: a new worry and cause for
vigilance. Int J Antimicrob Agents 47:1–3. https://doi.org/10.1016/
j.ijantimicag.2015.11.009.
125. Quesada A, Porrero MC, Tellez S, Palomo G, Garcia M, Dominguez L.
2015. Polymorphism of genes encoding PmrAB in colistin-resistant
strains of Escherichia coli and Salmonella enterica isolated from poultry
and swine. J Antimicrob Chemother 70:71–74. https://doi.org/10.1093/
jac/dku320.
126. Groisman EA. 2001. The pleiotropic two-component regulatory system
PhoP-PhoQ. J Bacteriol 183:1835–1842. https://doi.org/10.1128/JB
.183.6.1835-1842.2001.
127. Park SY, Groisman EA. 2014. Signal-speciﬁc temporal response by the
Salmonella PhoP/PhoQ regulatory system. Mol Microbiol 91:135–144.
https://doi.org/10.1111/mmi.12449.
128. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye
K, Jacobs MR, Bonomo RA, Adams MD. 2015. Genomic and transcrip-
tomic analyses of colistin-resistant clinical isolates of Klebsiella pneu-
moniae reveal multiple pathways of resistance. Antimicrob Agents
Chemother 59:536–543. https://doi.org/10.1128/AAC.04037-14.
129. Lippa AM, Goulian M. 2009. Feedback inhibition in the PhoQ/PhoP
592
signaling system by a membrane peptide. PLoS Genet 5:e1000788.
https://doi.org/10.1371/journal.pgen.1000788.
130. Cannatelli A, Giani T, D’Andrea MM, Di Pilato V, Arena F, Conte V,
Tryﬁnopoulou K, Vatopoulos A, Rossolini G. 2014. MgrB inactivation is
a common mechanism of colistin resistance in KPC-producing Klebsiella
pneumoniae of clinical origin. Antimicrob Agents Chemother 58:
5696–5703. https://doi.org/10.1128/AAC.03110-14.
131. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Turkoglu S,
Nordmann P. 2015. The mgrB gene as a key target for acquired resis-
tance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother
70:75–80. https://doi.org/10.1093/jac/dku323.
132. Lopez-Camacho E, Gomez-Gil R, Tobes R, Manrique M, Lorenzo M,
Galvan B, Salvarelli E, Moatassim Y, Salanueva IJ, Pareja E, Codoner FM,
Alvarez-Tejado M, Garcillan-Barcia MP, De la Cruz F, Mingorance J. 2014.
Genomic analysis of the emergence and evolution of multidrug resis-
tance during a Klebsiella pneumoniae outbreak including carbapenem
and colistin resistance. J Antimicrob Chemother 69:632–636. https://
doi.org/10.1093/jac/dkt419.
133. Jayol A, Poirel L, Villegas MV, Nordmann P. 2015. Modulation of mgrB
gene expression as a source of colistin resistance in Klebsiella oxytoca.
Int J Antimicrob Agents 46:108 –110. https://doi.org/10.1016/j
.ijantimicag.2015.02.015.
134. Olaitan AO, Rolain JM. 2015. Interruption of mgrB in the mediation of
colistin resistance in Klebsiella oxytoca. Int J Antimicrob Agents 46:
354–355. https://doi.org/10.1016/j.ijantimicag.2015.06.003.
135. Jayol A, Nordmann P, Desroches M, Descousser JW, Poirel L. 2016.
Acquisition of broad-spectrum cephalosporin resistance leading to
colistin resistance in Klebsiella pneumoniae. Antimicrob Agents Che-
mother 60:3199–3201. https://doi.org/10.1128/AAC.00237-16.
136. Zowawi HM, Forde BM, Alfaresi M, Alzarouni A, Farahat Y, Chong TM,
Yin WF, Chan KG, Li J, Schembri MA, Beatson SA, Paterson DL. 2015.
Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae. Sci
Rep 5:15082. https://doi.org/10.1038/srep15082.
137. Cheng YH, Lin TL, Lin YT, Wang JT. 2016. Amino acid substitutions of
CrrB responsible for resistance to colistin through CrrC in Klebsiella
pneumoniae. Antimicrob Agents Chemother 60:3709–3716. https://
doi.org/10.1128/AAC.00009-16.
138. De Majumdar S, Yu J, Fookes M, McAteer SP, Llobet E, Finn S, Spence
S, Monahan A, Kissenpfennig A, Ingram RJ, Bengoechea J, Gally DL,
Fanning S, Elborn JS, Schneiders T. 2015. Elucidation of the RamA
regulon in Klebsiella pneumoniae reveals a role in LPS regulation. PLoS
Pathog 11:e1004627. https://doi.org/10.1371/journal.ppat.1004627.
139. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong
B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z,
Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance
mechanism MCR-1 in animals and human beings in China: a microbi-
ological and molecular biological study. Lancet Infect Dis 16:161–168.
https://doi.org/10.1016/S1473-3099(15)00424-7.
140. Sherman EX, Hufnagel DA, Weiss DS. 2016. MCR-1 confers cross-
resistance to lysozyme. Lancet Infect Dis 16:1226–1227. https://doi.org/
10.1016/S1473-3099(16)30395-4.
141. Stojanoski V, Sankaran B, Prasad BV, Poirel L, Nordmann P, Palzkill T. 2016.
Structure of the catalytic domain of the colistin resistance enzyme MCR-1.
BMC Biol 14:81. https://doi.org/10.1186/s12915-016-0303-0.
142. Shen Z, Wang Y, Shen Y, Shen J, Wu C. 2016. Early emergence of mcr-1
in Escherichia coli from food-producing animals. Lancet Infect Dis 16:
293. https://doi.org/10.1016/S1473-3099(16)00061-X.
143. Zurfuh K, Poirel L, Nordmann P, Nuesch-Inderbinen M, Hachler H,
Stephan R. 2016. Occurrence of the plasmid-borne mcr-1 colistin resis-
tance gene in ESBL-producing Enterobacteriacae in river water and
imported vegetable samples in Switzerland. Antimicrob Agents Che-
mother 60:2594–2595. https://doi.org/10.1128/AAC.00066-16.
144. Poirel L, Nordmann P. 2016. Plasmid-encoded colistin resistance: the
animal world as the culprit? J Antimicrob Chemother 71:2326–2327.
https://doi.org/10.1093/jac/dkw074.
145. Thanh DP, Tuyen HT, Nguy T, Nguyen ET, The HC, Wick RR, Thwaites G,
Baker S, Holt KE. 2016. Inducible colistin resistance via a disrupted plasmid-
borne mcr-1 gene in a 2008 Vietnamese Shigella sonnei isolate. J Antimi-
crob Chemother 71:2314–2317. https://doi.org/10.1093/jac/dkw173.
146. Yao X, Doi Y, Zeng L, Lv L, Liu JH. 2016. Carbapenem-resistant and
colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet
Infect Dis 16:288 –289. https://doi.org/10.1016/S1473-3099(16)
00057-8.
147. Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the mcr-1
colistin resistance gene in carbapenem-resistant Enterobacteriaceae.
Lancet Infect Dis 16:287–288. https://doi.org/10.1016/S1473-3099
(16)00056-6.
148. Zhong LL, Zhang YF, Doi Y, Huang X, Zhang XF, Zeng KJ, Shen C, Patil
S, Xing Y, Zou Y, Tian GB. 2017. Coproduction of MCR-1 and NDM-1 by
colistin-resistant Escherichia coli isolated from a healthy individual.
Antimicrob Agents Chemother 61:e01962-16. https://doi.org/10.1128/
AAC.01962-16.
149. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. 2016. Plasmid-
mediated carbapenem and colistin resistance in a clinical isolate of
Escherichia coli. Lancet Infect Dis 16:281. https://doi.org/10.1016/S1473
-3099(16)00006-2.
150. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Kasbohrer A, Roesler
U, Michael GB, Schwarz S, Werner G, Kreienbrock L, Chakraborty T.
2016. Colistin resistance gene mcr-1 in extended-spectrum beta-
lactamase-producing and carbapenemase-producing Gram-negative
bacteria in Germany. Lancet Infect Dis 16:282–283. https://doi.org/
10.1016/S1473-3099(16)00009-8.
151. Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, Irwin
R, Melano RG. 2016. Dissemination of the mcr-1 colistin resistance gene.
Lancet Infect Dis 16:289–290. https://doi.org/10.1016/S1473-3099
(16)00067-0.
152. Liu BT, Song FJ, Zou M, Hao ZH, Shan H. 2017. Emergence of colistin
resistance gene mcr-1 in Cronobacter sakazakii producing NDM-9 and
Escherichia coli from the same animal. Antimicrob Agents Chemother
61:e01444-16. https://doi.org/10.1128/AAC.01444-16.
153. Zurﬂuh K, Tasara T, Poirel L, Nordmann P, Stephan R. 2016. Draft
genome sequence of Escherichia coli S51, a chicken isolate harboring a
chromosomally encoded mcr-1 gene. Genome Announc 4:e00796-16.
https://doi.org/10.1128/genomeA.00796-16.
154. Poirel L, Kieffer N, Brink A, Coetze J, Jayol A, Nordmann P. 2016. Genetic
features of MCR-1-producing colistin-resistant Escherichia coli isolates,
South Africa. Antimicrob Agents Chemother 60:4394–4397. https://
doi.org/10.1128/AAC.00444-16.
155. Snesrud E, He S, Chandler M, Dekker JP, Hickman AB, McGann P, Dyda
F. 2016. A model for transposition of the colistin resistance gene mcr-1
by ISApl1. Antimicrob Agents Chemother 60:6973–6976. https://
doi.org/10.1128/AAC.01457-16.
156. Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. 2016. Plasmid-
mediated colistin-resistant Escherichia coli in bacteremia in Switzerland.
Clin Infect Dis 62:1322–1323. https://doi.org/10.1093/cid/ciw124.
157. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L,
Fortunato S, Giani T, Menichetti F, Rossolini GM. 2016. mcr-1.2, a new
mcr variant carried on a transferable plasmid from a colistin-resistant
KPC carbapenemase-producing Klebsiella pneumoniae strain of se-
quence type 512. Antimicrob Agents Chemother 60:5612–5615.
https://doi.org/10.1128/AAC.01075-16.
158. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H,
Malhotra-Kumar S. 2016. Identiﬁcation of a novel plasmid-mediated
colistin-resistance gene,mcr-2, in Escherichia coli, Belgium, June 2016. Euro
Survei l l 21 :30280. https : / /doi .org/10 .2807/1560-7917.ES .
.21.27.30280.
159. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Ben-
goechea JA. 2004. Capsule polysaccharide mediates bacterial resis-
tance to antimicrobial peptides. Infect Immun 72:7107–7114. https://
doi.org/10.1128/IAI.72.12.7107-7114.2004.
160. Llobet E, Tomas JM, Bengoechea JA. 2008. Capsule polysaccharide is a
bacterial decoy for antimicrobial peptides. Microbiology 154:
3877–3886. https://doi.org/10.1099/mic.0.2008/022301-0.
161. Fresno S, Jimenez N, Izquierdo L, Merino S, Corsaro MM, De Castro C,
Parrilli M, Naldi T, Regue M, Tomas JM. 2006. The ionic interaction of
Klebsiella pneumoniae K2 capsule and core lipopolysaccharide. Micro-
biology 152:1807–1818. https://doi.org/10.1099/mic.0.28611-0.
162. Pilonieta MC, Erickson KD, Ernst RK, Detweiler CS. 2009. A protein
important for antimicrobial peptide resistance, YdeI/OmdA, is in the
periplasm and interacts with OmpD/NmpC. J Bacteriol 191:7243–7252.
https://doi.org/10.1128/JB.00688-09.
163. Padilla E, Llobet E, Domenech-Sanchez A, Martinez-Martinez L, Ben-
goechea JA, Alberti S. 2010. Klebsiella pneumoniae AcrAB efﬂux pump
contributes to antimicrobial resistance and virulence. Antimicrob
Agents Chemother 54:177–183. https://doi.org/10.1128/AAC.00715-09.
164. Srinivasan VB, Rajamohan G. 2013. KpnEF, a new member of the
Klebsiella pneumoniae cell envelope stress response regulon, is an
SMR-type efﬂux pump involved in broad-spectrum antimicrobial resis-
593
tance. Antimicrob Agents Chemother 57:4449–4462. https://doi.org/
10.1128/AAC.02284-12.
165. Ni W, Li Y, Guan J, Zhao J, Cui J, Wang R, Liu Y. 2016. Effects of efﬂux
pump inhibitors on colistin resistance in multidrug resistant Gram-
negative bacteria. Antimicrob Agents Chemother 60:3215–3218.
https://doi.org/10.1128/AAC.00248-16.
166. Lee JY, Ko KS. 2014. Mutations and expression of PmrAB and PhoPQ
related with colistin resistance in Pseudomonas aeruginosa clinical iso-
lates. Diagn Microbiol Infect Dis 78:271–276. https://doi.org/10.1016/
j.diagmicrobio.2013.11.027.
167. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK,
Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N.
2012. PmrB mutations promote polymyxin resistance of Pseudomonas
aeruginosa isolated from colistin-treated cystic ﬁbrosis patients. Anti-
microb Agents Chemother 56:1019–1030. https://doi.org/10.1128/
AAC.05829-11.
168. Barrow K, Kwon DH. 2009. Alterations in two-component regulatory
systems of phoPQ and pmrAB are associated with polymyxin B resis-
tance in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents
Chemother 53:5150–5154. https://doi.org/10.1128/AAC.00893-09.
169. Abraham N, Kwon DH. 2009. A single amino acid substitution in PmrB
is associated with polymyxin B resistance in clinical isolate of Pseu-
domonas aeruginosa. FEMS Microbiol Lett 298:249–254. https://
doi.org/10.1111/j.1574-6968.2009.01720.x.
170. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI,
Høiby N, Moskowitz SM. 2011. PhoQ mutations promote lipid A mod-
iﬁcation and polymyxin resistance of Pseudomonas aeruginosa found in
colistin-treated cystic ﬁbrosis patients. Antimicrob Agents Chemother
55:5761–5769. https://doi.org/10.1128/AAC.05391-11.
171. Muller C, Plesiat P, Jeannot K. 2011. A two-component regulatory
system interconnects resistance to polymyxins, aminoglycosides, ﬂuo-
roquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimi-
crob Agents Chemother 55:1211–1221. https://doi.org/10.1128/
AAC.01252-10.
172. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen
E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM. 2013. Polymyxin
resistance of Pseudomonas aeruginosa phoQ mutants is dependent on
additional two-component regulatory systems. Antimicrob Agents
Chemother 57:2204–2215. https://doi.org/10.1128/AAC.02353-12.
173. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs
MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter bauman-
nii associated with mutations in the PmrAB two-component system.
Antimicrob Agents Chemother 53:3628–3634. https://doi.org/10.1128/
AAC.00284-09.
174. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE.
2011. The pmrCAB operon mediates polymyxin resistance in Acineto-
bacter baumannii ATCC 17978 and clinical isolates through phosphoe-
thanolamine modiﬁcation of lipid A. Antimicrob Agents Chemother
55:3743–3751. https://doi.org/10.1128/AAC.00256-11.
175. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M,
Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoe-
thanolamine modiﬁcation of lipid A in colistin-resistant variants of
Acinetobacter baumannii mediated by the pmrAB two-component reg-
ulatory system. Antimicrob Agents Chemother 55:3370–3379. https://
doi.org/10.1128/AAC.00079-11.
176. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. 2014. In vivo emergence
of colistin resistance in Acinetobacter baumannii clinical isolates of
sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis
79:362–366. https://doi.org/10.1016/j.diagmicrobio.2014.03.027.
177. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-
Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G,
Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. 2013.
Emergence of colistin-resistance in extremely drug-resistant Acineto-
bacter baumannii containing a novel pmrCAB operon during colistin
therapy of wound infections. J Infect Dis 208:1142–1151. https://
doi.org/10.1093/infdis/jit293.
178. Park YK, Choi JY, Shin D, Ko KS. 2011. Correlation between overexpres-
sion and amino acid substitution of the PmrAB locus and colistin
resistance in Acinetobacter baumannii. Int J Antimicrob Agents 37:
525–530. https://doi.org/10.1016/j.ijantimicag.2011.02.008.
179. Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D,
Hardouin J, Cosette P, Tsakris A, Dé E. 2014. Growth retardation,
reduced invasiveness, and impaired colistin-mediated cell death asso-
ciated with colistin resistance development in Acinetobacter baumannii.
Antimicrob Agents Chemother 58:828–832. https://doi.org/10.1128/
AAC.01439-13.
180. Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. 2013.
Real-time sequencing to decipher the molecular mechanism of resis-
tance of a clinical pan-drug-resistant Acinetobacter baumannii isolate
from Marseille, France. Antimicrob Agents Chemother 57:592–596.
https://doi.org/10.1128/AAC.01314-12.
181. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion
sequence ISAba11 is involved in colistin resistance and loss of lipopoly-
saccharide in Acinetobacter baumannii. Antimicrob Agents Chemother
55:3022–3024. https://doi.org/10.1128/AAC.01732-10.
182. Ah YM, Kim AJ, Lee JY. 2014. Colistin resistance in Klebsiella pneu-
moniae. Int J Antimicrob Agents 44:8–15. https://doi.org/10.1016/
j.ijantimicag.2014.02.016.
183. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin
and polymyxin B against a worldwide collection of Gram-negative
pathogens: results from the SENTRY Antimicrobial Surveillance Pro-
gram (2006–09). J Antimicrob Chemother 66:2070–2074. https://
doi.org/10.1093/jac/dkr239.
184. Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG.
2009. In vitro activity of colistin (polymyxin E) against 3,480 isolates of
Gram-negative bacilli obtained from patients in Canadian hospitals in
the CANWARD study, 2007–2008. Antimicrob Agents Chemother 53:
4924–4926. https://doi.org/10.1128/AAC.00786-09.
185. Sutherland CA, Nicolau DP. 2015. Susceptibility proﬁle of ceftolozane/
tazobactam and other parenteral antimicrobials against Escherichia coli,
Klebsiella pneumoniae, and Pseudomonas aeruginosa from U.S. hospi-
tals. Clin Ther 37:1564 –1571. https://doi.org/10.1016/j.clinthera
.2015.05.501.
186. Tijet N, Sheth PM, Lastovetska O, Chung C, Patel SN, Melano RG. 2014.
Molecular characterization of Klebsiella pneumoniae carbapenemase
(KPC)-producing Enterobacteriaceae in Ontario, Canada, 2008–2011.
PLoS One 9:e116421. https://doi.org/10.1371/journal.pone.0116421.
187. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman
D. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn,
NY: molecular epidemiology and in vitro activity of polymyxin B and
other agents. J Antimicrob Chemother 56:128–132. https://doi.org/
10.1093/jac/dki175.
188. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ,
Muto CA, Doi Y. 2011. Colistin-resistant, Klebsiella pneumoniae carbap-
enemase (KPC)-producing Klebsiella pneumoniae belonging to the
international epidemic clone ST258. Clin Infect Dis 53:373–376. https://
doi.org/10.1093/cid/cir401.
189. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani
A, Navon-Venezia S, Hothi J, Slim J, Blunden C, Shango M, Lephart PR,
Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar
S, Bonomo RA, Kaye KS. 2011. Outbreak of colistin-resistant,
carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit,
Michigan. Antimicrob Agents Chemother 55:593–599. https://doi.org/
10.1128/AAC.01020-10.
190. Garza-Ramos U, Barrios H, Reyna-Flores F, Sanchez-Perez A, Tamayo-
Legorreta E, Ibarra-Pacheco A, Salazar-Salinas J, Nunez-Ceballos R,
Silva-Sanchez J. 2014. Characteristics of KPC-2-producing Klebsiella
pneumoniae (ST258) clinical isolates from outbreaks in 2 Mexican med-
ical centers. Diagn Microbiol Infect Dis 79:483–485. https://doi.org/
10.1016/j.diagmicrobio.2014.05.010.
191. Arduino SM, Quiroga MP, Ramirez MS, Merkier AK, Errecalde L, Di
Martino A, Smayevsky J, Kaufman S, Centron D. 2012. Transposons and
integrons in colistin-resistant clones of Klebsiella pneumoniae and Acin-
etobacter baumannii with epidemic or sporadic behaviour. J Med Mi-
crobiol 61:1417–1420. https://doi.org/10.1099/jmm.0.038968-0.
192. Weterings V, Zhou K, Rossen JW, van Stenis D, Thewessen E, Kluytmans
J, Veenemans J. 2015. An outbreak of colistin-resistant Klebsiella pneu-
moniae carbapenemase-producing Klebsiella pneumoniae in the Neth-
erlands (July to December 2013), with inter-institutional spread. Eur J
Clin Microbiol Infect Dis 34:1647–1655. https://doi.org/10.1007/s10096
-015-2401-2.
193. Toth A, Damjanova I, Puskas E, Janvari L, Farkas M, Dobak A, Borocz K,
Paszti J. 2010. Emergence of a colistin-resistant KPC-2-producing Kleb-
siella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect
Dis 29:765–769. https://doi.org/10.1007/s10096-010-0921-3.
194. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antonia-
dou E, Soﬁanou D. 2010. Hospital outbreak caused by Klebsiella pneu-
594
moniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp
Infect 76:70–73. https://doi.org/10.1016/j.jhin.2010.03.021.
195. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papado-
michelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H. 2007.
Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive
care unit patients: ﬁrst report of a multiclonal cluster. J Antimicrob Che-
mother 59:786–790. https://doi.org/10.1093/jac/dkl562.
196. Mezzatesta ML, Gona F, Caio C, Petrolito V, Sciortino D, Sciacca A,
Santangelo C, Stefani S. 2011. Outbreak of KPC-3-producing, and
colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hos-
pitals. Clin Microbiol Infect 17:1444–1447. https://doi.org/10.1111/
j.1469-0691.2011.03572.x.
197. Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C,
Saporito MA, Verde MS, Tetamo R, Palma DM. 2012. Ongoing spread of
colistin-resistant Klebsiella pneumoniae in different wards of an acute
general hospital, Italy, June to December 2011. Euro Surveill 17:20248.
198. Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L,
Fornaini R, Grazzini M, Niccolini F, Pecile P, Rossolini GM. 2015. Large
nosocomial outbreak of colistin-resistant, carbapenemase-producing
Klebsiella pneumoniae traced to clonal expansion of an mgrB deletion
mutant. J Clin Microbiol 53:3341–3344. https://doi.org/10.1128/
JCM.01017-15.
199. Parisi SG, Bartolini A, Santacatterina E, Castellani E, Ghirardo R, Berto A,
Franchin E, Menegotto N, De Canale E, Tommasini T, Rinaldi R, Basso M,
Stefani S, Palu G. 2015. Prevalence of Klebsiella pneumoniae strains
producing carbapenemases and increase of resistance to colistin in an
Italian teaching hospital from January 2012 to December 2014. BMC
Infect Dis 15:244. https://doi.org/10.1186/s12879-015-0996-7.
200. Mezzatesta ML, Caio C, Gona F, Cormaci R, Salerno I, Zingali T, Denaro
C, Gennaro M, Quattrone C, Stefani S. 2014. Carbapenem and multidrug
resistance in Gram-negative bacteria in a single centre in Italy: consid-
erations on in vitro assay of active drugs. Int J Antimicrob Agents
44:112–116. https://doi.org/10.1016/j.ijantimicag.2014.04.014.
201. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S,
Grundmann H, Pantosti A, Rossolini GM. 2014. Colistin resistance su-
perimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a
rapidly evolving problem in Italy, November 2013 to April 2014. Euro
Surveill 19:20939. https://doi.org/10.2807/1560-7917.ES2014.19
.42.20939.
202. Meletis G, Oustas E, Botziori C, Kakasi E, Koteli A. 2015. Containment of
carbapenem resistance rates of Klebsiella pneumoniae and Acinetobac-
ter baumannii in a Greek hospital with a concomitant increase in
colistin, gentamicin and tigecycline resistance. New Microbiol 38:
417–421.
203. Zagorianou A, Sianou E, Iosiﬁdis E, Dimou V, Protonotariou E, Miyakis S,
Roilides E, Soﬁanou D. 2012. Microbiological and molecular character-
istics of carbapenemase-producing Klebsiella pneumoniae endemic in a
tertiary Greek hospital during 2004–2010. Euro Surveill 17:20088.
204. Pena I, Picazo JJ, Rodriguez-Avial C, Rodriguez-Avial I. 2014.
Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in
Madrid, Spain: high percentage of colistin resistance among VIM-1-
producing Klebsiella pneumoniae ST11 isolates. Int J Antimicrob Agents
43:460–464. https://doi.org/10.1016/j.ijantimicag.2014.01.021.
205. Jayol A, Poirel L, Dortet L, Nordmann P. 2016. National survey of colistin
resistance among carbapenemase-producing Enterobacteriaceae and
outbreak caused by colistin-resistant OXA-48-producing Klebsiella
pneumoniae, France, 2014. Euro Surveill 21:30339. https://doi.org/
10.2807/1560-7917.ES.2016.21.37.30339.
206. Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH. 2010. Nonclonal
emergence of colistin-resistant Klebsiella pneumoniae isolates from
blood samples in South Korea. Antimicrob Agents Chemother 54:
560–562. https://doi.org/10.1128/AAC.00762-09.
207. Tan TY, Ng SY. 2006. The in-vitro activity of colistin in Gram-negative
bacteria. Singapore Med J 47:621–624.
208. Chen S, Hu F, Zhang X, Xu X, Liu Y, Zhu D, Wang H. 2011. Independent
emergence of colistin-resistant Enterobacteriaceae clinical isolates with-
out colistin treatment. J Clin Microbiol 49:4022–4023. https://doi.org/
10.1128/JCM.01233-11.
209. Chiu SK, Wu TL, Chuang YC, Lin JC, Fung CP, Lu PL, Wang JT, Wang LS,
Siu LK, Yeh KM. 2013. National surveillance study on carbapenem
non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and
rapid dissemination of KPC-2 carbapenemase. PLoS One 8:e69428.
https://doi.org/10.1371/journal.pone.0069428.
210. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE,
Papaioannou V, Ntani G, Samonis G, Falagas ME. 2008. Risk factors
associated with the isolation of colistin-resistant Gram-negative
bacteria: a matched case-control study. Crit Care Med 36:807–811.
https://doi.org/10.1097/CCM.0B013E3181652FAE.
211. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I,
Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou
H. 2011. Colonization and infection by colistin-resistant Gram-negative
bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17:
E9–E11. https://doi.org/10.1111/j.1469-0691.2011.03649.x.
212. Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-
Grauls CM. 2013. Emergence of colistin resistance in Enterobacteriaceae
after the introduction of selective digestive tract decontamination in an
intensive care unit. Antimicrob Agents Chemother 57:3224–3229.
https://doi.org/10.1128/AAC.02634-12.
213. Strenger V, Gschliesser T, Grisold A, Zarfel G, Feierl G, Masoud L,
Hoenigl M, Resch B, Muller W, Urlesberger B. 2011. Orally administered
colistin leads to colistin-resistant intestinal ﬂora and fails to prevent
faecal colonisation with extended-spectrum beta-lactamase-producing
enterobacteria in hospitalised newborns. Int J Antimicrob Agents 37:
67–69. https://doi.org/10.1016/j.ijantimicag.2010.09.010.
214. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M,
Zarrilli R. 2015. Emergence of colistin resistance without loss of ﬁtness
and virulence after prolonged colistin administration in a patient with
extensively drug-resistant Acinetobacter baumannii. Diagn Microbiol
Infect Dis 82:222–226. https://doi.org/10.1016/j.diagmicrobio.2015
.03.013.
215. Silvestri L, Taylor N, van Saene HK, Bakker J. 2014. Colistin, SDD and
resistance: nihil novi sub sole. Intensive Care Med 40:1065. https://
doi.org/10.1007/s00134-014-3321-9.
216. Zhao F, Zong Z. 2016. Kluyvera ascorbata strain from hospital sewage
carrying the mcr-1 colistin resistance gene. Antimicrob Agents Che-
mother 60:7498–7501.
217. Skov RL, Monnet DL. 2016. Plasmid-mediated colistin resistance (mcr-1
gene): three months later, the story unfolds. Euro Surveill 21:30155.
https://doi.org/10.2807/1560-7917.ES.2016.21.9.30155.
218. Hu Y, Liu F, Lin IY, Gao GF, Zhu B. 2016. Dissemination of the mcr-1
colistin resistance gene. Lancet Infect Dis 16:146–147. https://doi.org/
10.1016/S1473-3099(15)00533-2.
219. Ruppe E, Chatelier EL, Pons N, Andremont A, Ehrlich SD. 2016. Dissem-
ination of the mcr-1 colistin resistance gene. Lancet Infect Dis 16:
290–291. https://doi.org/10.1016/S1473-3099(16)00066-9.
220. Zhi C, Lv L, Yu LF, Doi Y, Liu JH. 2016. Dissemination of the mcr-1
colistin resistance gene. Lancet Infect Dis 16:292–293. https://doi.org/
10.1016/S1473-3099(16)00063-3.
221. Zhang R, Huang Y, Chan EW, Zhou H, Chen S. 2016. Dissemination of
themcr-1 colistin resistance gene. Lancet Infect Dis 16:291–292. https://
doi.org/10.1016/S1473-3099(16)00062-1.
222. Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. 2016. Dissemi-
nation of the mcr-1 colistin resistance gene. Lancet Infect Dis 16:147.
https://doi.org/10.1016/S1473-3099(15)00540-X.
223. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT, Pham NT,
Goossens H. 2016. Colistin-resistant Escherichia coli harbouring mcr-1
isolated from food animals in Hanoi, Vietnam. Lancet Infect Dis 16:
286–287. https://doi.org/10.1016/S1473-3099(16)00014-1.
224. Stoesser N, Mathers AJ, Moore CE, Day NP, Crook DW. 2016. Colistin
resistance gene mcr-1 and pHNSHP45 plasmid in human isolates of
Escherichia coli and Klebsiella pneumoniae. Lancet Infect Dis 16:
285–286. https://doi.org/10.1016/S1473-3099(16)00010-4.
225. Petrillo M, Angers-Loustau A, Kreysa J. 2016. Possible genetic events
producing colistin resistance gene mcr-1. Lancet Infect Dis 16:280.
https://doi.org/10.1016/S1473-3099(16)00005-0.
226. Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. 2016. Investi-
gation of a plasmid genome database for colistin-resistance gene
mcr-1. Lancet Infect Dis 16:284–285. https://doi.org/10.1016/S1473
-3099(16)00008-6.
227. Haenni M, Poirel L, Kieffer N, Chatre P, Saras E, Metayer V, Dumoulin R,
Nordmann P, Madec JY. 2016. Co-occurrence of extended spectrum
-lactamase and MCR-1 encoding genes on plasmids. Lancet Infect Dis
16:281–282. https://doi.org/10.1016/S1473-3099(16)00007-4.
228. Perrin-Guyomard A, Bruneau M, Houee P, Deleurme K, Legrandois P,
Poirier C, Soumet C, Sanders P. 2016. Prevalence ofmcr-1 in commensal
Escherichia coli from French livestock, 2007 to 2014. Euro Surveill
21:30135. https://doi.org/10.2807/1560-7917.ES.2016.21.6.30135.
229. Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM.
595
2016. First detection of the mcr-1 colistin resistance gene in Escherichia
coli, Italy. Antimicrob Agents Chemother 60:3257–3258. https://doi.org/
10.1128/AAC.00246-16.
230. Giufrè M, Monaco M, Accogli M, Pantosti A, Cerquetti M, PAMURSA
Study Group. 2016. Emergence of the colistin resistance mcr-1 deter-
minant in commensal Escherichia coli from residents of long-term-care
facilities in Italy. J Antimicrob Chemother 71:2329–2331. https://
doi.org/10.1093/jac/dkw195.
231. Doumith M, Godbole G, Ashton P, Larkin L, Dallman T, Day M, Day M,
Muller-Pebody B, Ellington MJ, de Pinna E, Johnson AP, Hopkins KL,
Woodford N. 2016. Detection of the plasmid-mediated mcr-1 gene
conferring colistin resistance in human and food isolates of Salmonella
enterica and Escherichia coli in England and Wales. J Antimicrob Che-
mother 71:2300–2305. https://doi.org/10.1093/jac/dkw093.
232. Kluytmans-van den Bergh MF, Huizinga P, Bonten MJ, Bos M, De Bruyne
K, Friedrich AW, Rossen JW, Savelkoul PH, Kluytmans JA. 2016. Presence
of mcr-1-positive Enterobacteriaceae in retail chicken meat but not in
humans in the Netherlands since 2009. Euro Surveill 21:30149. https://
doi.org/10.2807/1560-7917.ES.2016.21.9.30149.
233. Bonten MJ. 2016. Antimicrobial resistance: is it really all going wrong
now? Ned Tijdschr Geneeskd 160:D81.
234. Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J, de Jong
MD, Schultsz C. 2016. Dissemination of the mcr-1 colistin resistance
gene. Lancet Infect Dis 16:147–149. https://doi.org/10.1016/S1473
-3099(15)00541-1.
235. Veldman K, van Essen-Zandbergen A, Rapallini M, Wit B, Heymans R,
van Pelt W, Mevius D. 2016. Location of colistin resistance gene mcr-1
in Enterobacteriaceae from livestock and meat. J Antimicrob Chemother
71:2340–2342. https://doi.org/10.1093/jac/dkw181.
236. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agerso
Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS, Cavaco LM,
Hansen DS, Aarestrup FM, Skov RL. 2015. Detection of mcr-1 encoding
plasmid-mediated colistin-resistant Escherichia coli isolates from hu-
man bloodstream infection and imported chicken meat, Denmark
2015. Euro Surveill 20:30085. https://doi.org/10.2807/1560-7917
.ES.2015.20.49.30085.
237. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, Hinkle M,
Whitman T, Lesho E, Schaecher KE. 2016. Escherichia coli harboring
mcr-1 and blaCTX-M on a novel IncF plasmid: ﬁrst report of mcr-1 in the
United States. Antimicrob Agents Chemother 60:4420–4421. https://
doi.org/10.1128/AAC.01103-16.
238. Grami R, Mansour W, Mehri W, Bouallegue O, Boujaafar N, Madec JY,
Haenni M. 2016. Impact of food animal trade on the spread of mcr-1-
mediated colistin resistance, Tunisia, July 2015. Euro Surveill 21:30144.
https://doi.org/10.2807/1560-7917.ES.2016.21.8.30144.
239. Elnahriry SS, Khalifa HO, Soliman AM, Ahmed AM, Moustafa AH, Shi-
mamoto T. 2016. Emergence of plasmid-mediated colistin resistance gene,
mcr-1, in a clinical Escherichia coli isolate from Egypt. Antimicrob Agents
Chemother 60:3249–3250. https://doi.org/10.1128/AAC.00269-16.
240. Perreten V, Strauss C, Collaud A, Gerber D. 2016. Colistin resistance
gene mcr-1 in avian pathogenic Escherichia coli in South Africa. Anti-
microb Agents Chemother 60:4414–4415. https://doi.org/10.1128/
AAC.00548-16.
241. Fernandes MR, Moura Q, Sartori L, Silva KC, Cunha MP, Esposito F,
Lopes R, Otutumi LK, Gonçalves DD, Dropa M, Matté MH, Monte DF,
Landgraf M, Francisco GR, Bueno MF, de Oliveira Garcia D, Knöbl T,
Moreno AM, Lincopan N. 2016. Silent dissemination of colistin-resistant
Escherichia coli in South America could contribute to the global spread
of the mcr-1 gene. Euro Surveill 21:30214. https://doi.org/10.2807/1560
-7917.ES.2016.21.17.30214.
242. Zeng KJ, Doi Y, Patil S, Huang X, Tian GB. 2016. Emergence of plasmid-
mediated mcr-1 gene in colistin-resistant Enterobacter aerogenes and
Enterobacter cloacae. Antimicrob Agents Chemother 60:3862–3863.
https://doi.org/10.1128/AAC.00345-16.
243. Tse H, Yuen KY. 2016. Dissemination of the mcr-1 colistin resistance
gene. Lancet Infect Dis 16:145–146. https://doi.org/10.1016/S1473
-3099(15)00532-0.
244. Webb HE, Granier SA, Marault M, Millemann Y, den Bakker HC, Night-
ingale KK, Bugarel M, Ison SA, Scott HM, Loneragan GH. 2016. Dissem-
ination of the mcr-1 colistin resistance gene. Lancet Infect Dis 16:
144–145. https://doi.org/10.1016/S1473-3099(15)00538-1.
245. Iraz M, Ozad Duzgun A, Sandalli C, Doymaz MZ, Akkoyunlu Y, Saral A,
Peleg AY, Ozgumus OB, Beris FS, Karaoglu H, Copur Cicek A. 2015.
Distribution of beta-lactamase genes among carbapenem-resistant
Klebsiella pneumoniae strains isolated from patients in Turkey. Ann Lab
Med 35:595–601. https://doi.org/10.3343/alm.2015.35.6.595.
246. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. 2009.
Carbapenem resistance among Klebsiella pneumoniae isolates: risk fac-
tors, molecular characteristics, and susceptibility patterns. Infect Con-
trol Hosp Epidemiol 30:666–671. https://doi.org/10.1086/598244.
247. Lee JY, Chung ES, Na IY, Kim H, Shin D, Ko KS. 2014. Development of
colistin resistance in pmrA-, phoP-, parR- and cprR-inactivated mutants
of Pseudomonas aeruginosa. J Antimicrob Chemother 69:2966–2971.
https://doi.org/10.1093/jac/dku238.
596
